PESTICIDAL MIXTURES CONTAINING ISOXAZOLINE DERIVATIVES AND INSECTICIDE OR NEMATOICIDAL BIOLOGICAL AGENT

Abstract
The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula (I) wherein A1, A2, R1, R2, R3, R4 and R5 are as defined in claim 1 and one of Y1 and Y2 is S, SO or SO2 and the other is CH2 and component B is an insecticide or nematicidal biological agent as defined in claim 1. The present invention also relates to methods of using said mixtures for the control of pests.
Description

The present invention relates to mixtures of pesticidally active ingredients and to methods of using the mixtures in the field of agriculture.


WO 2009/080250 discloses that certain isoxazoline compounds have insecticidal activity.


The present invention provides pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula I




embedded image


wherein


one of Y1 and Y2 is S, SO or SO2 and the other is CH2;


L is a direct bond or methylene;


A1 and A2 are C—H, or one of A1 and A2 is C—H and the other is N;


R1 is hydrogen or methyl;


R2 is chlorodifluoromethyl or trifluoromethyl;


R3 is 3,5-dibromo-phenyl, 3,5-dichloro-phenyl, 3,4-dichloro-phenyl, or 3,4,5-trichlorophenyl;


R4 is methyl;


R5 is hydrogen;


or R4 and R5 together form a bridging 1,3-butadiene group;


and component B is a compound selected from


a) a pyrethroid including those selected from the group consisting of permethrin, cypermethrin, fenvalerate, esfenvalerate, deltamethrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, bifenthrin, fenpropathrin, cyfluthrin, tefluthrin, ethofenprox, natural pyrethrin, tetramethrin, S-bioallethrin, fenfluthrin, prallethrin and 5-benzyl-3-furylmethyl-(E)-(1R,3S)-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropane carboxylate;


b) an organophosphate including those selected from the group consisting of sulprofos, acephate, methyl parathion, azinphos-methyl, demeton-s-methyl, heptenophos, thiometon, fenamiphos, monocrotophos, profenofos, triazophos, methamidophos, dimethoate, phosphamidon, malathion, chlorpyrifos, phosalone, terbufos, fensulfothion, fonofos, phorate, phoxim, pirimiphos-methyl, pirimiphos-ethyl, fenitrothion, fosthiazate and diazinon;


c) a carbamate including those selected from the group consisting of pirimicarb, triazamate, cloethocarb, carbofuran, furathiocarb, ethiofencarb, aldicarb, thiofurox, carbosulfan, bendiocarb, fenobucarb, propoxur, methomyl and oxamyl;


d) a benzoyl urea including those selected from the group consisting of diflubenzuron, triflumuron, hexaflumuron, flufenoxuron, lufenuron and chlorfluazuron;


e) an organic tin compound including those selected from the group consisting of cyhexatin, fenbutatin oxide and azocyclotin;


f) a pyrazole including those selected from the group consisting of tebufenpyrad and fenpyroximate;


g) a macrolide including those selected from the group consisting of abamectin, emamectin (e.g. emamectin benzoate), ivermectin, milbemycin, spinosad, azadirachtin and spinetoram;


h) an organochlorine compound including those selected from the group consisting of endosulfan (in particular alpha-endosulfan), benzene hexachloride, DDT, chlordane and dieldrin;


i) an amidine including those selected from the group consisting of chlordimeform and amitraz;


j) a fumigant agent including those selected from the group consisting of chloropicrin, dichloropropane, methyl bromide and metam;


k) a neonicotinoid compound including those selected from the group consisting of imidacloprid, thiacloprid, acetamiprid, nitenpyram, dinotefuran, thiamethoxam, clothianidin, nithiazine and flonicamid;


l) a diacylhydrazine including those selected from the group consisting of tebufenozide, chromafenozide and methoxyfenozide;


m) a diphenyl ether including those selected from the group consisting of diofenolan and pyriproxyfen;


n) indoxacarb;


o) chlorfenapyr;


p) pymetrozine;


q) spirotetramat, spirodiclofen and spiromesifen;


r) a diamide including those selected from the group consisting of flubendiamide, chlorantraniliprole (Rynaxypyr®) and cyantraniliprole;


s) sulfoxaflor;


t) metaflumizone;


u) fipronil and ethiprole;


v) pyrifluqinazon;


w) buprofezin.


x) diafenthiuron; and


y) 4-[(6-Chloro-pyridin-3-ylmethyl)-(2,2-difluoro-ethyl)-amino]-5H-furan-2-one.


In addition, component B may be a nematicidally active biological agent. The nematicidally active biological agent refers to any biological agent that has nematicidal activity. The biological agent can be any type known in the art including bacteria and fungi. The wording “nematicidally active” refers to having an effect on, such as reduction in damage caused by, agricultural-related nematodes. The nematicidally active biological agent can be a bacterium or a fungus. Preferably, the biological agent is a bacterium. Examples of nematicidally active bacteria include Bacillus firmus, Bacillus cereus, Bacillus subtilis, and Pasteuria penetrans, preferably Bacillus firmus, Bacillus subtilis, and Pasteuria penetrans. A suitable Bacillus firmus strain is strain CNCM I-1582 which is commercially available as BioNem™. A suitable Bacillus cereus strain is strain CNCM I-1562. Of both Bacillus strains more details can be found in U.S. Pat. No. 6,406,690.


It has now been found, surprisingly, that the active ingredient mixture according to the invention not only delivers about the additive enhancement of the spectrum of action with respect to the pest to be controlled that was in principle to be expected but achieves a synergistic effect which can extend the range of action of the component A and of the component B in two ways. Firstly, the rates of application of the component A and of the component B are lowered whilst the action remains equally good. Secondly, the active ingredient mixture still achieves a high degree of pest control, sometimes even where the two individual components have become totally ineffective in such a low application rate range. This allows increased safety in use.


However, besides the actual synergistic action with respect to pest control, the pesticidal compositions according to the invention can have further surprising advantageous properties which can also be described, in a wider sense, as synergistic activity. Examples of such advantageous properties that may be mentioned are: a broadening of the spectrum of pest control to other pests, for example to resistant strains; a reduction in the rate of application of the active ingredients; adequate pest control with the aid of the compositions according to the invention, even at a rate of application at which the individual compounds are totally ineffective; advantageous behaviour during formulation and/or upon application, for example upon grinding, sieving, emulsifying, dissolving or dispensing; increased storage stability; improved stability to light; more advantageuos degradability; improved toxicological and/or ecotoxicological behaviour; improved characteristics of the useful plants including: emergence, crop yields, more developed root system, tillering increase, increase in plant height, bigger leaf blade, less dead basal leaves, stronger tillers, greener leaf colour, less fertilizers needed, less seeds needed, more productive tillers, earlier flowering, early grain maturity, less plant verse (lodging), increased shoot growth, improved plant vigor, and early germination; or any other advantages familiar to a person skilled in the art.


The compounds of formula I and their manufacturing processes are known from WO 2009/080250. The components B are known, e.g. from “The Pesticide Manual”, Fifteenth Edition, Edited by Clive Tomlin, British Crop Protection Council. The compound under y) is known from DE 102006015467. Reference to the above components B includes reference to their salts and any usual derivatives, such as ester derivatives.


The combinations according to the invention may also comprise more than one of the active components B, if, for example, a broadening of the spectrum of pest control is desired. For instance, it may be advantageous in the agricultural practice to combine two or three components B with any of the compounds of formula I, or with any preferred member of the group of compounds of formula I. The mixtures of the invention may also comprise other active ingredients in addition to components A and B. In other embodiments the mixtures of the invention may include only components A and B as pesticidally active ingredients, e.g. no more than two pesticidally active ingredients.


In one preferred group of compounds of formula I Y1 is S and Y2 is CH2.


In another preferred group of compounds of formula I Y1 is SO and Y2 is CH2.


In another preferred group of compounds of formula I Y1 is SO2 and Y2 is CH2.


In another preferred group of compounds of formula I Y2 is S and Y1 is CH2.


In another preferred group of compounds of formula I Y2 is SO and Y1 is CH2.


In another preferred group of compounds of formula I Y2 is SO2 and Y1 is CH2.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is S and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO2 and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is S and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; and R4 is methyl; and R4 and R5 together form a bridging 1,3-butadiene group.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; and R4 is methyl; and R4 and R5 together form a bridging 1,3-butadiene group.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO2 and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; and R4 is methyl; and R4 and R5 together form a bridging 1,3-butadiene group.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is S and the other is CH2; A1 is C—H; A2 is N; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO and the other is CH2; A1 is C—H; A2 is N; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO2 and the other is CH2; A1 is C—H; A2 is N; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond; Y1 is S, SO or SO2; Y2 is CH2; A1 is C—H; A2 is C—H; R1 is hydrogen; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is a direct bond; Y1 is S, SO or SO2; Y2 is CH2; A1 is C—H; A2 is C—H; R1 is methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is methylene; Y1 is CH2; Y2 is S, SO or SO2; A1 is C—H; A2 is C—H; R1 is hydrogen; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


In yet another preferred group of compounds of formula I L is methylene; Y1 is CH2; Y2 is S, SO or SO2; A1 is C—H; A2 is C—H; R1 is methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.


Preferably when L is a direct bond Y2 is CH2 and Y1 is S, SO or SO2 and when L is methylene Y2 is S, SO or SO2 and Y1 is CH2.


Each substituent definition in each preferred group of compounds of formula I may be juxtaposed with any substituent definition in any other preferred group of compounds, in any combination.


Compounds of formula I include at least one chiral centre and may exist as compounds of formula I* or compounds of formula I**.




embedded image


Compounds of formula I** are more biologically active than compounds of formula I* (confirmed by X-ray analysis). Component A may be a mixture of compounds I* and I** in any ratio e.g. in a molar ratio of 1:99 to 99:1, e.g. 10:1 to 1:10, e.g. a substantially 50:50 molar ratio. Preferably component A is a racemic mixture of the compounds of formula I** and I* or is enantiomerically enriched for the compound of formula I**. For example, when component A is an enantiomerically enriched mixture of formula I**, the molar proportion of compound I** compared to the total amount of both enantiomers is for example greater than 50%, e.g. at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or at least 99%.


Preferred compounds of formula I are shown in the Table below.









TABLE A







Compounds of formula I(a)










embedded image


(Ia)















Comp
Stereochemistry






No.
at *
L
R1
Y1
Y2















1
racemic mixture
bond
CH3
S
CH2


2
racemic mixture
bond
CH3
SO (cis)
CH2


3
racemic mixture
bond
CH3
SO (trans)
CH2


4
racemic mixture
bond
CH3
SO2
CH2


5
racemic mixture
bond
H
S
CH2


6
racemic mixture
bond
H
SO (cis)
CH2


7
racemic mixture
bond
H
SO (trans)
CH2


8
racemic mixture
bond
H
SO2
CH2


9
racemic mixture
CH2
CH3
CH2
S


10
racemic mixture
CH2
CH3
CH2
SO (cis)


11
racemic mixture
CH2
CH3
CH2
SO (trans)


12
racemic mixture
CH2
CH3
CH2
SO2


13
racemic mixture
CH2
H
CH2
S


14
racemic mixture
CH2
H
CH2
SO (cis)


15
racemic mixture
CH2
H
CH2
SO (trans)


16
racemic mixture
CH2
H
CH2
SO2


19
S
bond
CH3
S
CH2


20
S
bond
CH3
SO (cis)
CH2


21
S
bond
CH3
SO (trans)
CH2


22
S
bond
CH3
SO2
CH2


23
S
bond
H
S
CH2


24
S
bond
H
SO (cis)
CH2


25
S
bond
H
SO (trans)
CH2


26
S
bond
H
SO2
CH2


27
S
CH2
CH3
CH2
S


28
S
CH2
CH3
CH2
SO (cis)


29
S
CH2
CH3
CH2
SO (trans)


30
S
CH2
CH3
CH2
SO2


31
S
CH2
H
CH2
S


32
S
CH2
H
CH2
SO (cis)


33
S
CH2
H
CH2
SO (trans)


34
S
CH2
H
CH2
SO2





The symbol * indicates the location of the chiral centre






The present invention includes all isomers of compounds of formula (I), salts and N-oxides thereof, including enantiomers, diastereomers and tautomers. Component A may be a mixture of any type of isomer of a compound of formula I, or may be substantially a single type of isomer. For example, where Y1or Y2 is SO, component A may be a mixture of the cis and trans isomer in any ratio, e.g. in a molar ratio of 1:99 to 99:1, e.g. 10:1 to 1:10, e.g. a substantially 50:50 molar ratio. For example, in trans enriched mixtures of the compound of formula I, e.g. when Y1or Y2 is SO, the molar proportion of the trans compound in the mixture compared to the total amount of both cis and trans is for example greater than 50%, e.g. at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or at least 99%. Likewise, in cis enriched mixtures of the compound of formula I (preferred), e.g. when Y1 or Y2 is SO, the molar proportion of the cis compound in the mixture compared to the total amount of both cis and trans is for example greater than 50%, e.g. at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or at least 99%. The compound of formula I may be enriched for the trans sulphoxide. Likewise, the compound of formula I may be enriched for the cis sulphoxide. Y1or Y2 is SO for compounds 2, 3, 6, 7, 10, 11, 14, 15, 20, 21, 24, 25, 28, 29, 32 and 33 in Table A. Each may be a mixture which is enriched for the cis or trans isomer respectively.


In one embodiment of the invention component B is a compound selected from

    • pymetrozine;
    • an organophosphate selected from the group consisting of sulprofos, acephate, methyl parathion, azinphos-methyl, demeton-s-methyl, heptenophos, thiometon, fenamiphos, monocrotophos, profenofos, triazophos, methamidophos, dimethoate, phosphamidon, malathion, chlorpyrifos, phosalone, terbufos, fensulfothion, fonofos, phorate, phoxim, pirimiphos-methyl, pirimiphos-ethyl, fenitrothion, fosthiazate and diazinon;
    • a pyrethroid selected from the group consisting of permethrin, cypermethrin, fenvalerate, esfenvalerate, deltamethrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, bifenthrin, fenpropathrin, cyfluthrin, tefluthrin, ethofenprox, natural pyrethrin, tetramethrin, S-bioallethrin, fenfluthrin, prallethrin and 5-benzyl-3-furylmethyl-(E)-(1R,3S)-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropane carboxylate;
    • a macrolide selected from the group consisting of abamectin, emamectin benzoate, ivermectin, milbemycin, spinosad, azadirachtin and spinetoram;
    • a diamide selected from the group consisting of flubendiamide, chlorantraniliprole (Rynaxypyr®) and cyantraniliprole;
    • a neonicotinoid compound selected from the group consisting of imidacloprid, thiacloprid, acetamiprid, nitenpyram, dinotefuran, thiamethoxam, clothianidin, nithiazine and flonicamid;
    • spirotetramat, spirodiclofen and spiromesifen; and
    • sulfoxaflor, lufeneron, diafenthiuron, and fipronil.


Preferably component B is a compound selected from the group consisting of abamectin, chlorpyrifos, cyantraniliprole, emamectin, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid, chlorantraniliprole, flonicamid. sulfoxaflor, lufeneron, diafenthiuron, flubendiamide, tefluthrin, and fipronil. More preferably component B is a compound selected from the group consisting of abamectin, chlorpyrifos, cyantraniliprole, emamectin, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid and flonicamid.


In one embodiment component B is a compound selected from the group consisting of abamectin, chlorpyrifos, cyantraniliprole, emamectin, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid and chlorantraniliprole. In another embodiment component B is a compound selected from the group consisting of abamectin, chlorpyrifos, cyantraniliprole, emamectin, lambda cyhalothrin, pymetrozine, spirotetramat, and thiamethoxam.


The invention also includes the following combinations:


A mixture of a compound from Table A and abamectin.


A mixture of a compound from Table A and chlorpyrifos.


A mixture of a compound from Table A and cyantraniliprole.


A mixture of a compound from Table A and emamectin.


A mixture of a compound from Table A and cyhalothrin.


A mixture of a compound from Table A and lambda cyhalothrin.


A mixture of a compound from Table A and gamma cyhalothrin.


A mixture of a compound from Table A and pymetrozine.


A mixture of a compound from Table A and spirotetramat.


A mixture of a compound from Table A and thiamethoxam.


A mixture of a compound from Table A and chlorantraniliprole.


A mixture of a compound from Table A and profenofos.


A mixture of a compound from Table A and acephate.


A mixture of a compound from Table A and azinphos-methyl.


A mixture of a compound from Table A and methamidophos.


A mixture of a compound from Table A and spinosad.


A mixture of a compound from Table A and spinetoram.


A mixture of a compound from Table A and flonicamid.


A mixture of a compound from Table A and indoxacarb.


A mixture of a compound from Table A and spirodiclofen.


A mixture of a compound from Table A and spiromesifen.


A mixture of a compound from Table A and sulfoxaflor.


A mixture of a compound from Table A and fipronil.


A mixture of a compound from Table A and imidacloprid.


A mixture of a compound from Table A and thiacloprid.


A mixture of a compound from Table A and acetamiprid.


A mixture of a compound from Table A and nitenpyram.


A mixture of a compound from Table A and dinotefuran.


A mixture of a compound from Table A and clothianidin.


A mixture of a compound from Table A and nithiazine.


A mixture of a compound from Table A and pyriproxyfen.


A mixture of a compound from Table A and buprofezin.


A mixture of a compound from Table A and pyrifluqinazon.


A mixture of a compound from Table A, thiamethoxam and cyantraniliprole.


A mixture of a compound from Table A, thiamethoxam and chlorantraniliprole.


A mixture of a compound from Table A and sulfoxaflor.


A mixture of a compound from Table A and Lufeneron.


A mixture of a compound from Table A and Diafenthiuron.


A mixture of a compound from Table A and Flubendiamide.


A mixture of a compound from Table A and Tefluthrin.


A mixture of a compound from Table A and Fipronil.


The present invention also relates to a method of controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest a combination of components A and B; seeds comprising a mixture of components A and B; and a method comprising coating a seed with a mixture of components A and B.


Components A and B may be provided and/or used in amounts such that they are capable of synergistic pest control. For example, For example, the present invention includes pesticidal mixtures comprising a component A and a component B in a synergistically effective amount; agricultural compositions comprising a mixture of component A and B in a synergistically effective amount; the use of a mixture of component A and B in a synergistically effective amount for combating animal pests; a method of combating animal pests which comprises contacting the animal pests, their habit, breeding ground, food supply, plant, seed, soil, area, material or environment in which the animal pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from animal attack or infestation with a mixture of component A and B in a synergistically effective amount; a method for protecting crops from attack or infestation by animal pests which comprises contacting a crop with a mixture of component A and B in a synergistically effective amount; a method for the protection of seeds from soil insects and of the seedlings' roots and shoots from soil and foliar insects comprising contacting the seeds before sowing and/or after pre-germination with a mixture of component A and B in a synergistically effective amount; seeds comprising, e.g. coated with, a mixture of component A and B in a synergistically effective amount; a method comprising coating a seed with a mixture of component A and B in a synergistically effective amount; a method of controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest a combination of components A and B in a synergistically effective amount. Mixtures of A and B will normally be applied in an insecticidally, acaricidally, nematicidally or molluscicidally effective amount. In application components A and B may be applied simultaneously or separately.


The mixtures of the present invention can be used to control infestations of insect pests such as Lepidoptera, Diptera, Hemiptera, Thysanoptera, Orthoptera, Dictyoptera, Coleoptera, Siphonaptera, Hymenoptera and Isoptera and also other invertebrate pests, for example, acarine, nematode and mollusc pests. Insects, acarines, nematodes and molluscs are herein collectively referred to as pests. The pests which may be controlled by the use of the invention compounds include those pests associated with agriculture (which term includes the growing of crops for food and fiber products), horticulture and animal husbandry, companion animals, forestry and the storage of products of vegetable origin (such as fruit, grain and timber); those pests associated with the damage of man-made structures and the transmission of diseases of man and animals; and also nuisance pests (such as flies). The mixtures of the invention are particularly effective against insects, acarines and/or nematodes.


According to the invention “useful plants” typically comprise the following species of plants: grape vines; cereals, such as wheat, barley, rye or oats; beet, such as sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, for example apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries or blackberries; leguminous plants, such as beans, lentils, peas or soybeans; oil plants, such as rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans or groundnuts; cucumber plants, such as marrows, cucumbers or melons; fibre plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruit or mandarins; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceae, such as avocados, cinnamon or camphor; maize; tobacco; nuts; coffee; sugar cane; tea; vines; hops; durian; bananas; natural rubber plants; turf or ornamentals, such as flowers, shrubs, broad-leaved trees or evergreens, for example conifers. This list does not represent any limitation.


The term “useful plants” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.


The term “useful plants” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.


Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins, for example insecticidal proteins from Bacillus cereus or Bacillus popliae; or insecticidal proteins from Bacillus thuringiensis, such as δ-endotoxins, e.g. CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c, or vegetative insecticidal proteins (VIP), e.g. VIP1, VIP2, VIP3 or VIP3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsine inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.


In the context of the present invention there are to be understood by δ-endotoxins, for example CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c, or vegetative insecticidal proteins (VIP), for example VIP1, VIP2, VIP3 or VIP3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701). An example for a truncated toxin is a truncated CryIA(b), which is expressed in the Btl 1 maize from Syngenta Seed SAS, as described below. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of CryIIIA055, a cathepsin-D-recognition sequence is inserted into a CryIIIA toxin (see WO 03/018810)


Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO 93/07278, WO 95/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.


The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90/13651.


The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).


Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard® (maize variety that expresses a CryIA(b) toxin); YieldGard Rootworm® (maize variety that expresses a CryIIIB(b1) toxin); YieldGard Plus® (maize variety that expresses a CryIA(b) and a CryIIIB(b1) toxin); Starlink® (maize variety that expresses a Cry9(c) toxin); Herculex I® (maize variety that expresses a CryIF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CryIA(c) toxin); Bollgard I® (cotton variety that expresses a CryIA(c) toxin); Bollgard II® (cotton variety that expresses a CryIA(c) and a CryIIA(b) toxin); VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potato variety that expresses a CryIIIA toxin); NatureGard® and Protecta®.


Further examples of such transgenic crops are:


1. Btl1 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated CryIA(b) toxin. Btl1 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.


2. Bt176 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a CryIA(b) toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.


3. MIR604 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified CryIIIA toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-D-protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810.


4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a CryIIIB(b1) toxin and has resistance to certain Coleoptera insects.


5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02.


6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein CryI F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.


7. NK603×MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603×MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CryIA(b) toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain Lepidoptera, include the European corn borer.


Transgenic crops of insect-resistant plants are also described in BATS (Zentrum für Biosicherheit and Nachhaltigkeit, Zentrum BATS, Clarastrasse 13, 4058 Basel, Switzerland) Report 2003, (http://bats.ch).


The term “useful plants” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called “pathogenesis-related proteins” (PRPs, see e.g. EP-A-0 392 225). Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0 392 225, WO 95/33818, and EP-A-0 353 191. The methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.


Antipathogenic substances which can be expressed by such transgenic plants include, for example, ion channel blockers, such as blockers for sodium and calcium channels, for example the viral KP1, KP4 or KP6 toxins; stilbene synthases; bibenzyl synthases; chitinases; glucanases; the so-called “pathogenesis-related proteins” (PRPs; see e.g. EP-A-0 392 225); antipathogenic substances produced by microorganisms, for example peptide antibiotics or heterocyclic antibiotics (see e.g. WO 95/33818) or protein or polypeptide factors involved in plant pathogen defence (so-called “plant disease resistance genes”, as described in WO 03/000906).


Useful plants of elevated interest in connection with present invention are cereals; soybean; rice; oil seed rape; pome fruits; stone fruits; peanuts; coffee; tea; strawberries; turf; vines and vegetables, such as tomatoes, potatoes, cucurbits and lettuce.


The term “locus” of a useful plant as used herein is intended to embrace the place on which the useful plants are growing, where the plant propagation materials of the useful plants are sown or where the plant propagation materials of the useful plants will be placed into the soil. An example for such a locus is a field, on which crop plants are growing.


The term “plant propagation material” is understood to denote generative parts of a plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably “plant propagation material” is understood to denote seeds. Insecticides that are of particular interest for treating seeds include thiamethoxam, imidacloprid and clothianidin. Accordingly, in one embodiment component B is selected from thiamethoxam, imidacloprid and clothianidin.


A further aspect of the instant invention is a method of protecting natural substances of plant and/or animal origin, which have been taken from the natural life cycle, and/or their processed forms against attack of pests, which comprises applying to said natural substances of plant and/or animal origin or their processed forms a combination of components A and B in a synergistically effective amount.


According to the instant invention, the term “natural substances of plant origin, which have been taken from the natural life cycle” denotes plants or parts thereof which have been harvested from the natural life cycle and which are in the freshly harvested form. Examples of such natural substances of plant origin are stalks, leafs, tubers, seeds, fruits or grains. According to the instant invention, the term “processed form of a natural substance of plant origin” is understood to denote a form of a natural substance of plant origin that is the result of a modification process. Such modification processes can be used to transform the natural substance of plant origin in a more storable form of such a substance (a storage good). Examples of such modification processes are pre-drying, moistening, crushing, comminuting, grounding, compressing or roasting. Also falling under the definition of a processed form of a natural substance of plant origin is timber, whether in the form of crude timber, such as construction timber, electricity pylons and barriers, or in the form of finished articles, such as furniture or objects made from wood.


According to the instant invention, the term “natural substances of animal origin, which have been taken from the natural life cycle and/or their processed forms” is understood to denote material of animal origin such as skin, hides, leather, furs, hairs and the like.


A preferred embodiment is a method of protecting natural substances of plant origin, which have been taken from the natural life cycle, and/or their processed forms against attack of pests, which comprises applying to said natural substances of plant and/or animal origin or their processed forms a combination of components A and B in a synergistically effective amount.


A further preferred embodiment is a method of protecting fruits, preferably pomes, stone fruits, soft fruits and citrus fruits, which have been taken from the natural life cycle, and/or their processed forms, which comprises applying to said fruits and/or their processed forms a combination of components A and B in a synergistically effective amount.


The combinations according to the present invention are furthermore particularly effective against the following pests: Myzus persicae (aphid), Aphis gossypii (aphid), Aphis fabae (aphid), Lygus spp. (capsids), Dysdercus spp. (capsids), Nilaparvata lugens (planthopper), Nephotettixc incticeps (leafhopper), Nezara spp. (stinkbugs), Euschistus spp. (stinkbugs), Leptocorisa spp. (stinkbugs), Frankliniella occidentalis (thrip), Thrips spp. (thrips), Leptinotarsa decemlineata (Colorado potato beetle), Anthonomus grandis (boll weevil), Aonidiella spp. (scale insects), Trialeurodes spp. (white flies), Bemisia tabaci (white fly), Ostrinia nubilalis (European corn borer), Spodoptera littoralis (cotton leafworm), Heliothis virescens (tobacco budworm), Helicoverpa armigera (cotton bollworm), Helicoverpa zea (cotton bollworm), Sylepta derogata (cotton leaf roller), Pieris brassicae (white butterfly), Plutella xylostella (diamond back moth), Agrotis spp. (cutworms), Chilo suppressalis (rice stem borer), Locusta migratoria (locust), Chortiocetes terminifera (locust), Diabrotica spp. (rootworms), Panonychus ulmi (European red mite), Panonychus citri (citrus red mite), Tetranychus urticae (two-spotted spider mite), Tetranychus cinnabarinus (carmine spider mite), Phyllocoptruta oleivora (citrus rust mite), Polyphagotarsonemus latus (broad mite), Brevipalpus spp. (flat mites), Boophilus microplus (cattle tick), Dermacentor variabilis (American dog tick), Ctenocephalides felis (cat flea), Liriomyza spp. (leafminer), Musca domestica (housefly), Aedes aegypti (mosquito), Anopheles spp. (mosquitoes), Culex spp. (mosquitoes), Lucillia spp. (blowflies), Blattella germanica (cockroach), Periplaneta americana (cockroach), Blatta orientalis (cockroach), termites of the Mastotermitidae (for example Mastotermes spp.), the Kalotermitidae (for example Neotermes spp.), the Rhinotermitidae (for example Coptotermes formosanus, Reticulitermes flavipes, R. speratu, R. virginicus, R. hesperus, and R. santonensis) and the Termitidae (for example Globitermes sulfureus), Solenopsis geminata (fire ant), Monomorium pharaonis (pharaoh's ant), Damalinia spp. and Linognathus spp. (biting and sucking lice), Meloidogyne spp. (root knot nematodes), Globodera spp. and Heterodera spp. (cyst nematodes), Pratylenchus spp. (lesion nematodes), Rhodopholus spp. (banana burrowing nematodes), Tylenchulus spp. (citrus nematodes), Haemonchus contortus (barber pole worm), Caenorhabditis elegans (vinegar eelworm), Trichostrongylus spp. (gastro intestinal nematodes) and Deroceras reticulatum (slug).


The mixtures of the invention may be used for pest control on various plants, including soybean, corn, sugarcane, alfalfa, brassicas, oilseed rape (e.g. canola), potatoes (including sweet potatoes), cotton, rice, coffee, citrus, almonds, fruiting vegetables (e.g. tomatoes, pepper, chili, eggplant, cucumber, squash etc.), tea, bulb vegetables (e.g. onion, leek etc.), grapes, pome fruit (e.g. apples, pears etc.), and stone fruit (e.g. pears, plums etc.).


The mixtures of the invention may be used on soybean to control, for example, Elasmopalpus lignosellus, Diloboderus abderus, Diabrotica speciosa, Sternechus subsignatus, Formicidae, Agrotis ypsilon, Julus sspp., Anticarsia gemmatalis, Megascelis ssp., Procornitermes ssp., Gryllotalpidae, Nezara viridula, Piezodorus spp., Acrosternum spp., Neomegalotomus spp., Cerotoma trifurcata, Popillia japonica, Edessa spp., Liogenys fuscus, Euchistus heros, stalk borer, Scaptocoris castanea, phyllophaga spp., Pseudoplusia includens, Spodoptera spp., Bemisia tabaci, Agriotes spp. The mixtures of the invention are preferably used on soybean to control Diloboderus abderus, Diabrotica speciosa, Nezara viridula, Piezodorus spp., Acrosternum spp., Cerotoma trifurcata, Popillia japonica, Euchistus heros, phyllophaga spp., Agriotes sp


The mixtures of the invention may be used on corn to control, for example, Euchistus heros, Dichelops furcatus, Diloboderus abderus, Elasmopalpus lignosellus, Spodoptera frugiperda, Nezara viridula, Cerotoma trifurcata, Popillia japonica, Agrotis ypsilon, Diabrotica speciosa, Heteroptera, Procornitermes ssp., Scaptocoris castanea, Formicidae, Julus ssp., Dalbulus maidis, Diabrotica virgifera, Mocis latipes, Bemisia tabaci, heliothis spp., Tetranychus spp., thrips spp., phyllophaga spp., scaptocoris spp., Liogenys fuscus, Spodoptera spp., Ostrinia spp., Sesamia spp., Agriotes spp. The mixtures of the invention are preferably used on corn to control Euchistus heros, Dichelops furcatus, Diloboderus abderus, Nezara viridula, Cerotoma trifurcata, Popillia japonica, Diabrotica speciosa, Diabrotica virgifera, Tetranychus spp., thrips spp., phyllophaga spp., scaptocoris spp., Agriotes spp.


The mixtures of the invention may be used on sugar cane to control, for example, Sphenophorus spp., termites, Mahanarva spp. The mixtures of the invention are preferably used on sugar cane to control termites, Mahanarva spp.


The mixtures of the invention may be used on alfalfa to control, for example, Hypera brunneipennis, Hypera postica, Colias eurytheme, Collops spp., Empoasca solana, Epitrix, Geocoris spp., Lygus hesperus, Lygus lineolaris, Spissistilus spp., Spodoptera spp., Trichoplusia ni. The mixtures of the invention are preferably used on alfalfa to control Hypera brunneipennis, Hypera postica, Empoasca solana, Epitrix, Lygus hesperus, Lygus lineolaris, Trichoplusia ni.


The mixtures of the invention may be used on brassicas to control, for example, Plutella xylostella, Pieris spp., Mamestra spp., Plusia spp., Trichoplusia ni, Phyllotreta spp., Spodoptera spp., Empoasca solana, thrips spp., Spodoptera spp., Delia spp. The mixtures of the invention are preferably used on brassicas to control Plutella xylostella Pieris spp., Plusia spp., Trichoplusia ni, Phyllotreta spp., thrips sp


The mixtures of the invention may be used on oil seed rape, e.g. canola, to control, for example, Meligethes spp., Ceutorhynchus napi, Psylloides spp.


The mixtures of the invention may be used on potatoes, including sweet potatoes, to control, for example, Empoasca spp., Leptinotarsa spp., Diabrotica speciosa, Phthorimaea spp., Paratrioza spp., Maladera matrida, Agriotes spp. The mixtures of the invention are preferably used on potatoes, including sweet potatoes, to control Empoasca spp., Leptinotarsa spp., Diabrotica speciosa, Phthorimaea spp., Paratrioza spp., Agriotes spp.


The mixtures of the invention may be used on cotton to control, for example, Anthonomus grandis, Pectinophora spp., heliothis spp., Spodoptera spp., Tetranychus spp., Empoasca spp., thrips spp., Bemisia tabaci, Lygus spp., phyllophaga spp., Scaptocoris spp. The mixtures of the invention are preferably used on cotton to control Anthonomus grandis, Tetranychus spp., Empoasca spp., thrips spp., Lygus spp., phyllophaga spp., Scaptocoris spp.


The mixtures of the invention may be used on rice to control, for example, Leptocorisa spp., Cnaphalocrosis spp., Chilo spp., Scirpophaga spp., Lissorhoptrus spp., Oebalus pugnax. The mixtures of the invention are preferably used on rice to control Leptocorisa spp., Lissorhoptrus spp., Oebalus pugnax.


The mixtures of the invention may be used on coffee to control, for example, Hypothenemus Hampei, Perileucoptera Coffeella, Tetranychus spp. The mixtures of the invention are preferably used on coffee to control Hypothenemus Hampei, Perileucoptera Coffeella.


The mixtures of the invention may be used on citrus to control, for example, Panonychus citri, Phyllocoptruta oleivora, Brevipalpus spp., Diaphorina citri, Scirtothrips spp., thrips spp., Unaspis spp., Ceratitis capitata, Phyllocnistis spp. The mixtures of the invention are preferably used on citrus to control Panonychus citri, Phyllocoptruta oleivora, Brevipalpus spp., Diaphorina citri, Scirtothrips spp., thrips spp., Phyllocnistis spp.


The mixtures of the invention may be used on almonds to control, for example, Amyelois transitella, Tetranychus spp.


The mixtures of the invention may be used on fruiting vegetable, including tomatoes, pepper, chili, eggplant, cucumber, squash etc, to control thrips spp., Tetranychus spp., Polyphagotarsonemus spp., Aculops spp., Empoasca spp., Spodoptera spp., heliothis spp., Tuta absoluta, Liriomyza spp., Bemisia tabaci, Trialeurodes spp., Paratrioza spp., Frankliniella occidentalis, Frankliniella spp., Anthonomus spp., Phyllotreta spp., Amrasca spp., Epilachna spp., Halyomorpha spp., Scirtothrips spp., Leucinodes spp., Neoleucinodes spp. The mixtures of the invention are preferably used on fruiting vegetable, including tomatoes, pepper, chili, eggplant, cucumber, squash etc, to control, for example, thrips spp., Tetranychus spp., Polyphagotarsonemus spp., Aculops spp., Empoasca spp., Spodoptera spp., heliothis spp., Tuta absoluta, Liriomyza spp., Paratrioza spp., Frankliniella occidentalis, Frankliniella spp., Amrasca spp., Scirtothrips spp., Leucinodes spp., Neoleucinodes spp.


The mixtures of the invention may be used on tea to control, for example, Pseudaulacaspis spp., Empoasca spp., Scirtothrips spp., Caloptilia theivora. The mixtures of the invention are prefrerably used on tea to control Empoasca spp., Scirtothrips spp.


The mixtures of the invention may be used on bulb vegetables, including onion, leek etc to control, for example, thrips spp., Spodoptera spp., heliothis spp. The mixtures of the invention are preferably used on bulb vegetables, including onion, leek etc to control thrips spp.


The mixtures of the invention may be used on grapes to control, for example, Empoasca spp., Lobesia spp., Frankliniella spp., thrips spp., Tetranychus spp., Rhipiphorothrips Cruentatus, Eotetranychus Willamettei, Erythroneura Elegantula, Scaphoides spp. The mixtures of the invention are preferably used on grapes to control Frankliniella spp., thrips spp., Tetranychus spp., Rhipiphorothrips Cruentatus, Scaphoides spp.


The mixtures of the invention may be used on pome fruit, including apples, pairs etc, to control, for example, Cacopsylla spp., Psylla spp., Panonychus ulmi, Cydia pomonella. The mixtures of the invention are preferably used on pome fruit, including apples, pairs etc, to control Cacopsylla spp., Psylla spp., Panonychus ulmi.


The mixtures of the invention may be used on stone fruit to control, for example, Grapholita molesta, Scirtothrips spp., thrips spp., Frankliniella spp., Tetranychus spp. The mixtures of the invention are preferably used on stone fruit to control Scirtothrips spp., thrips spp., Frankliniella spp., Tetranychus spp.


The amount of a combination of the invention to be applied, will depend on various factors, such as the compounds employed; the subject of the treatment, such as, for example plants, soil or seeds; the type of treatment, such as, for example spraying, dusting or seed dressing; the purpose of the treatment, such as, for example prophylactic or therapeutic; the type of pest to be controlled or the application time.


The mixtures comprising a compound of formula I, e.g. those selected from table A, and one or more active ingredients as described above can be applied, for example, in a single “ready-mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula I selected from table A and the active ingredients as described above is not essential for working the present invention.


The synergistic activity of the combination is apparent from the fact that the pesticidal activity of the composition of A+B is greater than the sum of the pesticidal activities of A and B.


The method of the invention comprises applying to the useful plants, the locus thereof or propagation material thereof in admixture or separately, a synergistically effective aggregate amount of a component A and a component B.


Some of said combinations according to the invention have a systemic action and can be used as foliar, soil and seed treatment pesticides.


With the combinations according to the invention it is possible to inhibit or destroy the pests which occur in plants or in parts of plants (fruit, blossoms, leaves, stems, tubers, roots) in different useful plants, while at the same time the parts of plants which grow later are also protected from attack by pests.


The combinations of the present invention are of particular interest for controlling pests in various useful plants or their seeds, especially in field crops such as potatoes, tobacco and sugarbeets, and wheat, rye, barley, oats, rice, maize, lawns, cotton, soybeans, oil seed rape, pulse crops, sunflower, coffee, sugarcane, fruit and ornamentals in horticulture and viticulture, in vegetables such as cucumbers, beans and cucurbits.


The combinations according to the invention are applied by treating the pests, the useful plants, the locus thereof, the propagation material thereof, the natural substances of plant and/or animal origin, which have been taken from the natural life cycle, and/or their processed forms, or the industrial materials threatened by pests, attack with a combination of components A and B in a synergistically effective amount.


The combinations according to the invention may be applied before or after infection or contamination of the useful plants, the propagation material thereof, the natural substances of plant and/or animal origin, which have been taken from the natural life cycle, and/or their processed forms, or the industrial materials by the pests.


The combinations according to the invention can be used for controlling, i.e. containing or destroying, pests of the abovementioned type which occur on useful plants in agriculture, in horticulture and in forests, or on organs of useful plants, such as fruits, flowers, foliage, stalks, tubers or roots, and in some cases even on organs of useful plants which are formed at a later point in time remain protected against these pests.


When applied to the useful plants the compound of formula I is generally applied at a rate of 1 to 500 g a.i./ha in association with 1 to 2000 g a.i./ha, of a compound of component B, depending on the class of chemical employed as component B.


Generally for plant propagation material, such as seed treatment, application rates can vary from 0.001 to 10 g/kg of seeds of active ingredients. When the combinations of the present invention are used for treating seed, rates of 0.001 to 5 g of a compound of formula I per kg of seed, preferably from 0.01 to 1 g per kg of seed, and 0.001 to 5 g of a compound of component B, per kg of seed, preferably from 0.01 to 1 g per kg of seed, are generally sufficient.


The weight ratio of A to B may generally be between 1000:1 and 1:1000. In other embodiments that weight ratio of A to B may be between 500:1 to 1:500, for example between 100:1 to 1:100, for example between 1:50 to 50:1, for example 1:20 to 20:1. Other embodiments of weight ratios of component (B) to component (A) range from 500:1 to 1:250, with one embodiment being from 200:1 to 1:150, another embodiment being from 150:1 to 1:50 and another embodiment being from 50:1 to 1:10. Also of note are weight ratios of component (B) to component (A) which range from 450:1 to 1:300, with one embodiment being from 150:1 to 1:100, another embodiment being from 30:1 to 1:25 and another embodiment being from 10:1 to 1:10.


The invention also provides pesticidal mixtures comprising a combination of components A and B as mentioned above in a synergistically effective amount, together with an agriculturally acceptable carrier, and optionally a surfactant.



Spodoptera preferably means Spodoptera littoralis. Heliothis preferably means Heliothis virescens. Tetranychus preferably means Tetranychus urticae.


The compositions of the invention may be employed in any conventional form, for example in the form of a twin pack, a powder for dry seed treatment (DS), an emulsion for seed treatment (ES), a flowable concentrate for seed treatment (FS), a solution for seed treatment (LS), a water dispersible powder for seed treatment (WS), a capsule suspension for seed treatment (CF), a gel for seed treatment (GF), an emulsion concentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK), a dispersible concentrate (DC), a wettable powder (WP), a soluble granule (SG) or any technically feasible formulation in combination with agriculturally acceptable adjuvants.


Such compositions may be produced in conventional manner, e.g. by mixing the active ingredients with appropriate formulation inerts (diluents, solvents, fillers and optionally other formulating ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners and compounds that provide adjuvancy effects). Also conventional slow release formulations may be employed where long lasting efficacy is intended. Particularly formulations to be applied in spraying forms, such as water dispersible concentrates (e.g. EC, SC, DC, OD, SE, EW, EO and the like), wettable powders and granules, may contain surfactants such as wetting and dispersing agents and other compounds that provide adjuvancy effects, e.g. the condensation product of formaldehyde with naphthalene sulphonate, an alkylarylsulphonate, a lignin sulphonate, a fatty alkyl sulphate, and ethoxylated alkylphenol and an ethoxylated fatty alcohol.


A seed dressing formulation is applied in a manner known per se to the seeds employing the combination of the invention and a diluent in suitable seed dressing formulation form, e.g. as an aqueous suspension or in a dry powder form having good adherence to the seeds. Such seed dressing formulations are known in the art. Seed dressing formulations may contain the single active ingredients or the combination of active ingredients in encapsulated form, e.g. as slow release capsules or microcapsules. A typical a tank-mix formulation for seed treatment application comprises 0.25 to 80%, especially 1 to 75%, of the desired ingredients, and 99.75 to 20%, especially 99 to 25%, of a solid or liquid auxiliaries (including, for example, a solvent such as water), where the auxiliaries can be a surfactant in an amount of 0 to 40%, especially 0.5 to 30%, based on the tank-mix formulation. A typical pre-mix formulation for seed treatment application comprises 0.5 to 99.9%, especially 1 to 95%, of the desired ingredients, and 99.5 to 0.1%, especially 99 to 5%, of a solid or liquid adjuvant (including, for example, a solvent such as water), where the auxiliaries can be a surfactant in an amount of 0 to 50%, especially 0.5 to 40%, based on the pre-mix formulation.


In general, the formulations include from 0.01 to 90% by weight of active agent, from 0 to 20% agriculturally acceptable surfactant and 10 to 99.99% solid or liquid formulation inerts and adjuvant(s), the active agent consisting of at least the compound of formula I together with a compound of component B, and optionally other active agents, particularly microbiocides or conservatives or the like. Concentrated forms of compositions generally contain in between about 2 and 80%, preferably between about 5 and 70% by weight of active agent. Application forms of formulation may for example contain from 0.01 to 20% by weight, preferably from 0.01 to 5% by weight of active agent. Whereas commercial products will preferably be formulated as concentrates, the end user will normally employ diluted formulations.







EXAMPLES

A synergistic effect exists whenever the action of an active ingredient combination is greater than the sum of the actions of the individual components.


The action to be expected E for a given active ingredient combination obeys the so-called COLBY formula and can be calculated as follows (COLBY, S.R. “Calculating synergistic and antagonistic responses of herbicide combination”. Weeds, Vol. 15, pages 20-22; 1967):


ppm=milligrams of active ingredient (=a.i.) per liter of spray mixture


X=% action by active ingredient A) using p ppm of active ingredient


Y=% action by active ingredient B) using q ppm of active ingredient.


According to COLBY, the expected (additive) action of active ingredients A)+B) using p+q ppm of active ingredient is






E
=

X
+
Y
-


X
·
Y

100






If the action actually observed (O) is greater than the expected action (E), then the action of the combination is super-additive, i.e. there is a synergistic effect. In mathematical terms the synergism factor SF corresponds to O/E. In the agricultural practice an SF of ≧1.2 indicates significant improvement over the purely complementary addition of activities (expected activity), while an SF of ≦0.9 in the practical application routine signals a loss of activity compared to the expected activity.


Tables 1 to 123 show mixtures and compositions of the present invention demonstrating control on a wide range of invertebrate pests, some with notable synergistic effect. As the percent of mortality cannot exceed 100 percent, the unexpected increase in insecticidal activity can be greatest only when the separate active ingredient components alone are at application rates providing considerably less than 100 percent control. Synergy may not be evident at low application rates where the individual active ingredient components alone have little activity. However, in some instances high activity was observed for combinations wherein individual active ingredient alone at the same application rate had essentially no activity. The synergism is remarkable.


Noteworthy are mixtures comprising A1 and abamectin, chlorpyrifos, cyantraniliprole, emamectin benzoate, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid or flonicamid; mixtures comprising A5 and abamectin, chlorpyrifos, cyantraniliprole, emamectin benzoate, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid or flonicamid; mixtures comprising A6 and abamectin, chlorpyrifos, cyantraniliprole, emamectin benzoate, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid or flonicamid; mixtures comprising A6 and A7 and abamectin, chlorpyrifos, cyantraniliprole, emamectin benzoate, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid or flonicamid; mixtures comprising A8 and abamectin, chlorpyrifos, cyantraniliprole, emamectin benzoate, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid or flonicamid.



Spodoptera Littoralis (Egyptian Cotton Leaf Worm)

(Larvicide L1, Feeding/Contact)

Cotton leaf discs are placed on agar in Petri dishes and sprayed with test solutions in an application chamber. After drying, the leaf discs are infested with 10 L1 larvae. The samples are checked for mortality 5 days after treatment. 3 replicates per treatment were evaluated. Application rates are as indicated in the Tables. (1 PPM=1 mg l−1)












TABLE 1









EXPECT-
OB-



AVERAGE DEAD IN %
ED
SERVED


PPM Al
AFTER 5 DAYS
MORTAL-
MORTAL-












A1
Abamectin
A1
Abamectin
ITY
ITY















0.4
0.4
20
10
28
33*


0.4
0.8
20
13
31
37*


0.4
1.6
20
40
52
47 


0.8
0.4
50
10
55
50 


0.8
0.8
50
13
57
53 


0.8
1.6
50
40
70
90*



















TABLE 2









EXPECT-
OB-



AVERAGE DEAD IN %
ED
SERVED


PPM Al
AFTER 5 DAYS
MORTAL-
MORTAL-












A1
Chlorpyriphos
A1
Chlorpyriphos
ITY
ITY















0.4
12.5
20
10
28
30*


0.4
25
20
17
33
37*


0.4
50
20
30
44
37 


0.8
12.5
50
10
55
53 


0.8
25
50
17
58
60*


0.8
50
50
30
65
80*



















TABLE 3







PPM Al
AVERAGE DEAD IN % AFTER 5 DAYS
EXPECTED
OBSERVED












A1
Cyantraniliprole
A1
Cyantraniliprole
MORTALITY
MORTALITY















0.4
0.0125
37
23
51
40 


0.4
0.025
37
27
54
40 


0.4
0.05
37
40
62
90*


0.8
0.0125
67
23
74
83*


0.8
0.025
67
27
76
87*


0.8
0.05
67
40
80
93*



















TABLE 4








AVERAGE DEAD IN




PPM Al
% AFTER 5 DAYS















Emamectin

Emamectin
EXPECTED
OBSERVED


A1
Benzoate
A1
Benzoate
MORTALITY
MORTALITY





0.4
0.003125
37
20
49
37 


0.4
0.00625 
37
23
51
70*


0.4
0.0125 
37
30
56
73*


0.8
0.003125
67
20
73
77*


0.8
0.00625 
67
23
74
80*


0.8
0.0125 
67
30
77
83*



















TABLE 5








AVERAGE DEAD IN




PPM Al
% AFTER 5 DAYS















Lambda

Lambda
EXPECTED
OBSERVED


A1
Cyhalothrin
A1
Cyhalothrin
MORTALITY
MORTALITY





0.4
0.05
 7
10
16
20*


0.4
0.1 
 7
13
19
30*


0.4
0.2 
 7
17
22
30*


0.8
0.05
27
10
34
40*


0.8
0.1 
27
13
36
63*


0.8
0.2 
27
17
39
67*



















TABLE 6








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED












A1
Pymetrozine
A1
Pymetrozine
MORTALITY
MORTALITY





0.4
100
 7
17
22
20


0.4
200
 7
20
25
23


0.8
100
27
17
39
27


0.8
200
27
20
41
33



















TABLE 7








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED












A1
Spirotetramat
A1
Spirotetramat
MORTALITY
MORTALITY





0.4
 25
40
10
46
50*


0.4
 50
40
17
50
57*


0.4
100
40
43
66
83*


0.8
 25
47
10
52
57*


0.8
 50
47
17
56
93*


0.8
100
47
43
70
97*



















TABLE 8








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED












A1
Thiamethoxam
A1
Thiamethoxam
MORTALITY
MORTALITY





0.4
0.2
40
 7
44
40 


0.4
0.4
40
13
48
53*


0.4
0.8
40
30
58
60*


0.8
0.2
47
 7
50
53*


0.8
0.4
47
13
54
57*


0.8
0.8
47
30
63
73*



















TABLE 9








AVERAGE DEAD IN




PPM Al
% AFTER 5 DAYS
EXPECTED
OBSERVED












A5
Abamectin
A5
Abamectin
MORTALITY
MORTALITY





0.1
0.4
23
10
31
27 


0.1
0.8
23
13
34
30 


0.1
1.6
23
40
54
47 


0.2
0.4
67
10
70
73*


0.2
0.8
67
13
71
73*


0.2
1.6
67
40
80
77 



















TABLE 10








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED












A5
Chlorpyriphos
A5
Chlorpyriphos
MORTALITY
MORTALITY















0.1
12.5
23
10
31
30 


0.1
25
23
17
36
43*


0.1
50
23
30
46
47*


0.2
12.5
67
10
70
67 


0.2
25
67
17
72
73*


0.2
50
67
30
77
80*



















TABLE 11








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS















Cyan-

Cyan-
EXPECTED
OBSERVED


A5
traniliprole
A5
traniliprole
MORTALITY
MORTALITY





0.1
0.0125
30
23
46
47*


0.1
0.025 
30
27
49
70*


0.1
0.05 
30
40
58
77*


0.2
0.0125
50
23
62
63*


0.2
0.025 
50
27
63
87*


0.2
0.05 
50
40
70
97*



















TABLE 12








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS















Emamectin

Emamectin
EXPECTED
OBSERVED


A5
Benzoate
A5
Benzoate
MORTALITY
MORTALITY





0.1
0.003125
30
20
44
33 


0.1
0.00625 
30
23
46
50*


0.1
0.0125 
30
30
51
50 


0.2
0.003125
50
20
60
53 


0.2
0.00625 
50
23
62
53 


0.2
0.0125 
50
30
65
60 



















TABLE 13








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS















Lambda

Lambda
EXPECTED
OBSERVED


A5
Cyhalothrin
A5
Cyhalothrin
MORTALITY
MORTALITY















0.1
0.05
20
10
28
20 


0.1
0.1
20
13
31
20 


0.1
0.2
20
17
33
30 


0.2
0.05
23
10
31
23 


0.2
0.1
23
13
34
30 


0.2
0.2
23
17
36
37*



















TABLE 14








AVERAGE DEAD





IN % AFTER




PPM Al
5 DAYS
EXPECTED
OBSERVED












A5
Pymetrozine
A5
Pymetrozine
MORTALITY
MORTALITY





0.1
100
20
17
33
23 


0.1
200
20
20
36
23 


0.2
100
23
17
36
30 


0.2
200
23
20
39
47*



















TABLE 15








AVERAGE





DEAD IN %




PPM Al
AFTER5 DAYS
EXPECTED
OBSERVED












A5
Spirotetramat
A5
Spirotetramat
MORTALITY
MORTALITY





0.1
 25
27
10
34
 60*


0.1
 50
27
17
39
 60*


0.1
100
27
43
58
100*


0.2
 25
47
10
52
 67*


0.2
 50
47
17
56
 90*


0.2
100
47
43
70
100*



















TABLE 16








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED












A5
Thiamethoxam
A5
Thiamethoxam
MORTALITY
MORTALITY





0.1
0.2
27
 7
32
27 


0.1
0.4
27
13
36
27 


0.1
0.8
27
30
49
50*


0.2
0.2
47
 7
50
53*


0.2
0.4
47
13
54
53 


0.2
0.8
47
30
63
53 



















TABLE 17








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED












A6
Abamectin
A6
Abamectin
MORTALITY
MORTALITY





0.05
0.4
 7
 7
13
 7


0.1 
0.4
20
 7
25
20


0.2 
0.4
50
 7
53
50


0.05
0.8
 7
10
16
10


0.1 
0.8
20
10
28
23


0.2 
0.8
50
10
55
50


0.05
1.6
 7
20
25
20


0.1 
1.6
20
20
36
27


0.2 
1.6
50
20
60
60



















TABLE 18








AVERAGE





DEAD IN %




PPM Al
AFTER 5 DAYS
EXPECTED
OBSERVED













Chlor-

Chlor-




A6
pyriphos
A6
pyriphos
MORTALITY
MORTALITY















0.05
12.5
 7
 7
13
 7


0.1 
12.5
20
 7
25
23


0.2 
12.5
50
 7
53
50


0.05
25
 7
10
16
13


0.1 
25
20
10
28
27


0.2 
25
50
10
55
53


0.05
50
 7
20
25
20


0.1 
50
20
20
36
 43*


0.2 
50
50
20
60
 63*




















TABLE 19










EXPECT-
OB-





ED
SERVED




AVERAGE DEAD IN %
MOR-
MOR-










PPM AI
AFTER 5 DAYS
TAL-
TAL-












A6
Cyantraniliprole
A6
Cyantraniliprole
ITY
ITY















0.05
0.0125
7
23
28
23 


0.1
0.0125
17
23
36
37*


0.2
0.0125
47
23
59
77*


0.05
0.025
7
30
35
30 


0.1
0.025
17
30
42
37 


0.2
0.025
47
30
63
83*


0.05
0.05
7
50
53
67 


0.1
0.05
17
50
58
70 


0.2
0.05
47
50
73
83 



















TABLE 20







PPM AI
AVERAGE DEAD IN %
EXPECTED
OBSERVED












Emamectin
AFTER 5 DAYS
MORTAL-
MORTAL-












A6
Benzoate
A6
Emamectin Benzoate
ITY
ITY















0.05
0.003125
7
20
25
20 


0.1
0.003125
17
20
33
27 


0.2
0.003125
47
20
57
80*


0.05
0.00625
7
23
28
27 


0.1
0.00625
17
23
36
30 


0.2
0.00625
47
23
59
83*


0.05
0.0125
7
27
32
27 


0.1
0.0125
17
27
39
30 


0.2
0.0125
47
27
61
90*



















TABLE 21







PPM AI
AVERAGE DEAD IN %
EXPECTED
OBSERVED












Lambda
AFTER 5 DAYS
MORTAL-
MORTAL-












A6
Cyhalothrin
A6
Lambda Cyhalothrin
ITY
ITY















0.05
0.05
7
20
25
20 


0.1
0.05
17
20
33
23 


0.2
0.05
50
20
60
57 


0.05
0.1
7
37
41
40 


0.1
0.1
17
37
47
50*


0.2
0.1
50
37
68
67 


0.05
0.2
7
57
60
57 


0.1
0.2
17
57
64
70*


0.2
0.2
50
57
78
77 




















TABLE 22









AVERAGE

OB-




DEAD IN %
EXPECTED
SERVED










PPM AI
AFTER 5 DAYS
MORTAL-
MORTAL-












A6
Pymetrozine
A6
Pymetrozine
ITY
ITY















0.05
100
7
7
13
10 


0.1
100
17
7
22
20 


0.2
100
50
7
53
50 


0.05
200
7
17
22
17 


0.1
200
17
17
31
20 


0.2
200
50
17
58
60*




















TABLE 23









AVERAGE

OB-




DEAD IN %
EXPECTED
SERVED










PPM AI
AFTER 5 DAYS
MORTAL-
MORTAL-












A6
Spirotetramat
A6
Spirotetramat
ITY
ITY















0.05
25
7
23
28
 23 


0.1
25
13
23
34
 27 


0.2
25
40
23
54
 90*


0.05
50
7
33
38
 43*


0.1
50
13
33
42
 63*


0.2
50
40
33
60
 97*


0.05
100
7
67
69
 70*


0.1
100
13
67
71
 90 


0.2
100
40
67
80
100*




















TABLE 24









AVERAGE






DEAD IN %
EX-
OB-










PPM AI
AFTER 5 DAYS
PECTED
SERVED













Thiameth-

Thiameth-
MORTAL-
MORTAL-


A6
oxam
A6
oxam
ITY
ITY















0.05
0.2
7
10
16
13 


0.1
0.2
13
10
22
23 


0.2
0.2
40
10
46
40 


0.05
0.4
7
13
19
13 


0.1
0.4
13
13
25
33*


0.2
0.4
40
13
48
40 


0.05
0.8
7
30
35
30 


0.1
0.8
13
30
39
40*


0.2
0.8
40
30
58
43 




















TABLE 25









AVERAGE






DEAD IN %
EXPECTED
OBSERVED










PPM AI
AFTER 5 DAYS
MORTAL-
MORTAL-












A8
Abamectin
A8
Abamectin
ITY
ITY















0.05
0.4
10
7
16
10 


0.1
0.4
23
7
28
27 


0.2
0.4
53
7
56
57*


0.05
0.8
10
10
19
13 


0.1
0.8
23
10
31
27 


0.2
0.8
53
10
58
57 


0.05
1.6
10
20
28
20 


0.1
1.6
23
20
39
30 


0.2
1.6
53
20
63
57 




















TABLE 26









AVERAGE






DEAD IN %
EX-
OB-










PPM AI
AFTER 5 DAYS
PECTED
SERVED













Chlor-

Chlor-
MORTAL-
MORTAL-


A8
pyriphos
A8
pyriphos
ITY
ITY















0.05
12.5
10
7
16
10 


0.1
12.5
23
7
28
23 


0.2
12.5
53
7
56
53 


0.05
25
10
10
19
13 


0.1
25
23
10
31
23 


0.2
25
53
10
58
57 


0.05
50
10
20
28
20 


0.1
50
23
20
39
40*


0.2
50
53
20
63
60 




















TABLE 27









AVERAGE






DEAD IN %
EX-
OB-










PPM AI
AFTER 5 DAYS
PECTED
SERVED













Cyantran-

Cyantran-
MORTAL-
MORTAL-


A8
iliprole
A8
iliprole
ITY
ITY















0.05
0.0125
20
23
39
 27 


0.1
0.0125
30
23
46
 30 


0.2
0.0125
50
23
62
 80*


0.05
0.025
20
30
44
 33 


0.1
0.025
30
30
51
 47 


0.2
0.025
50
30
65
 83*


0.05
0.05
20
50
60
 53 


0.1
0.05
30
50
65
 57 


0.2
0.05
50
50
75
100*



















TABLE 28







PPM AI
AVERAGE DEAD IN %
EXPECTED
OBSERVED












Emamectin
AFTER 5 DAYS
MORTAL-
MORTAL-












A8
Benzoate
A8
Emamectin Benzoate
ITY
ITY















0.05
0.003125
20
20
36
27 


0.1
0.003125
30
20
44
30 


0.2
0.003125
50
20
60
50 


0.05
0.00625
20
23
39
27 


0.1
0.00625
30
23
46
30 


0.2
0.00625
50
23
62
63*


0.05
0.0125
20
27
41
33 


0.1
0.0125
30
27
49
37 


0.2
0.0125
50
27
63
83*



















TABLE 29







PPM AI
AVERAGE DEAD IN %
EXPECTED
OBSERVED












Lambda
AFTER 5 DAYS
MORTAL-
MORTAL-












A8
Cyhalothrin
A8
Lambda Cyhalothrin
ITY
ITY















0.05
0.05
10
20
28
20 


0.1
0.05
20
20
36
37*


0.2
0.05
53
20
63
53 


0.05
0.1
10
37
43
37 


0.1
0.1
20
37
49
40 


0.2
0.1
53
37
70
60 


0.05
0.2
10
57
61
57 


0.1
0.2
20
57
65
60 


0.2
0.2
53
57
80
73 




















TABLE 30









AVERAGE DEAD IN %
EXPECTED
OBSERVED










PPM AI
AFTER 5 DAYS
MORTAL-
MORTAL-












A8
Pymetrozine
A8
Pymetrozine
ITY
ITY















0.05
100
10
7
16
17*


0.1
100
20
7
25
20 


0.2
100
53
7
56
53 


0.05
200
10
17
25
20 


0.1
200
20
17
33
30 


0.2
200
53
17
61
57 




















TABLE 31









AVERAGE






DEAD IN %
EXPECTED
OBSERVED










PPM AI
AFTER 5 DAYS
MORTAL-
MORTAL-












A8
Spirotetramat
A8
Spirotetramat
ITY
ITY















0.05
25
13
23
34
 23 


0.1
25
23
23
41
 70*


0.2
25
40
23
54
 90*


0.05
50
13
33
42
 43*


0.1
50
23
33
49
 87*


0.2
50
40
33
60
100*


0.05
100
13
67
71
 77*


0.1
100
23
67
74
 97*


0.2
100
40
67
80
100*




















TABLE 32









AVERAGE






DEAD IN %
EXPECTED
OBSERVED










PPM AI
AFTER 5 DAYS
MORTAL-
MORTAL-












A8
Thiamethoxam
A8
Thiamethoxam
ITY
ITY















0.05
0.2
13
10
22
13


0.1
0.2
23
10
31
23


0.2
0.2
40
10
46
40


0.05
0.4
13
13
25
13


0.1
0.4
23
13
34
23


0.2
0.4
40
13
48
40


0.05
0.8
13
30
39
30


0.1
0.8
23
30
46
33


0.2
0.8
40
30
58
53










Heliothis Virescens (Tobacco Budworm):

(Ovo-Larvicide, Feeding/Contact)

30-35 fresh eggs (0-24 h old), deposited on filter paper, are placed in Petri dishes on top of a layer of artificial diet and 0.8 ml of diluted test solutions are pipetted onto them. After an incubation period of 7 days, samples are checked for egg and larval mortality. 3 replicates per treatment were evaluated. Application rates are as indicated in the Tables.












TABLE 33








AVERAGE DEAD




PPM AI
IN % (LARVAE)
EXPECTED
OBSERVED












A1
Abamectin
A1
Abamectin
MORTALITY
MORTALITY















0.2
0.025
17
3
19
30*


0.2
0.05
17
37
48
27 


0.2
0.1
17
53
61
40 


0.4
0.025
60
3
61
33 


0.4
0.05
60
37
75
47 


0.4
0.1
60
53
81
67 


0.8
0.025
87
3
87
47 


0.8
0.05
87
37
92
57 


0.8
0.1
87
53
94
67 



















TABLE 34








AVERAGE





DEAD IN %




PPM AI
(LARVAE)
EXPECTED
OBSERVED












A1
Chlorpyrifos
A1
Chlorpyrifos
MORTALITY
MORTALITY















0.2
50
0
0
0
30*


0.2
100
0
0
0
17*


0.2
200
0
30
30
63*


0.4
50
37
0
37
77*


0.4
100
37
0
37
70*


0.4
200
37
30
56
93*


0.8
50
67
0
67
77 


0.8
100
67
0
67
90 


0.8
200
67
30
77
97 



















TABLE 35








AVERAGE





DEAD IN %




PPM AI
(LARVAE)















Cyan-

Cyan-
EXPECTED
OBSERVED


A1
traniliprole
A1
traniliprole
MORTALITY
MORTALITY















0.2
0.2
13
23
33
23


0.2
0.4
13
70
74
70


0.2
0.8
13
82
84
78


0.4
0.2
68
23
75
57


0.4
0.4
68
70
90
78


0.4
0.8
68
82
94
90


0.8
0.2
73
23
79
72


0.8
0.4
73
70
92
67


0.8
0.8
73
82
95
85



















TABLE 36









AVERAGE











DEAD IN %



PPM AI
(LARVAE)














Emamectin

Emamectin
EXPECTED
OBSERVED


A1
benzoate
A1
benzoate
MORTALITY
MORTALITY















0.2
0.0015
10
5
15
5


0.2
0.003
10
5
15
10 


0.2
0.006
10
10
19
27*


0.4
0.0015
47
5
50
53*


0.4
0.003
47
5
50
70*


0.4
0.006
47
10
52
57*


0.8
0.0015
67
5
69
70*


0.8
0.003
67
5
69
73*


0.8
0.006
67
10
70
73*



















TABLE 37









AVERAGE











DEAD IN %



PPM AI
(LARVAE)














Lambda

Lambda
EXPECTED
OBSERVED


A1
Cyhalothrin
A1
Cyhalothrin
MORTALITY
MORTALITY















0.2
0.05
24
33
49
 80*


0.2
0.1
24
100
100
100


0.2
0.2
24
100
100
100


0.4
0.05
61
33
74
 80*


0.4
0.1
61
100
100
100


0.4
0.2
61
100
100
100


0.8
0.05
72
33
81
 73


0.8
0.1
72
100
100
100


0.8
0.2
72
100
100
100



















TABLE 38









AVERAGE












DEAD IN %




PPM AI
(LARVAE)















Pymetro-

Pymetro-
EXPECTED
OBSERVED


A1
zine
A1
zine
MORTALITY
MORTALITY















0.2
100
13
0
13
60*


0.2
200
13
40
48
53*


0.4
100
68
0
68
83*


0.4
200
68
40
81
73 


0.8
100
73
0
73
82*


0.8
200
73
40
84
75 



















TABLE 39









AVERAGE












DEAD IN %




PPM AI
(LARVAE)
EXPECTED
OBSERVED












A1
Spirotetramat
A1
Spirotetramat
MORTALITY
MORTALITY















0.2
100
13
78
81
60


0.2
200
13
100
100



0.4
100
68
78
93
78


0.4
200
68
100
100
100


0.8
100
73
78
94
83


0.8
200
73
100
100
100



















TABLE 40









AVERAGE












DEAD IN %




PPM AI
(LARVAE)















Thia-

Thia-
EXPECTED
OBSERVED


A1
methoxam
A1
methoxam
MORTALITY
MORTALITY















0.2
100
13
78
81
72


0.2
200
13
80
83
73


0.4
100
68
78
93
88


0.4
200
68
80
94
87


0.8
100
73
78
94
90


0.8
200
73
80
95
63



















TABLE 41









AVERAGE












DEAD IN %




PPM AI
(LARVAE)
EXPECTED
OBSERVED












A5
Abamectin
A5
Abamectin
MORTALITY
MORTALITY















0.025
0.025
3
3
6
 37*


0.025
0.05
3
37
39
 40*


0.025
0.1
3
53
54
 63*


0.05
0.025
33
3
35
33


0.05
0.05
33
37
58
53


0.05
0.1
33
53
69
50


0.1
0.025
53
3
54
50


0.1
0.05
53
37
70
53


0.1
0.1
53
53
78
67




















TABLE 42









AVERAGE DEAD
EXPECTED
OBSERVED










PPM AI
IN % (LARVAE)
MORTAL-
MORTAL-












A5
Chlorpyrifos
A5
Chlorpyrifos
ITY
ITY















0.025
50
0
0
0
0


0.025
100
0
0
0
0


0.025
200
0
30
30
73*


0.05
50
7
0
7
43*


0.05
100
7
0
7
47*


0.05
200
7
30
35
87*


0.1
50
67
0
67
80*


0.1
100
67
0
67
90*


0.1
200
67
30
77
100* 



















TABLE 43









AVERAGE














DEAD IN %












PPM AI
(LARVAE)
EXPECTED
OBSERVED













Cyan-

Cyan-
MORTAL-
MORTAL-


A5
traniliprole
A5
traniliprole
ITY
ITY















0.025
0.2
12
23
32
20


0.025
0.4
12
63
67
62


0.025
0.8
12
72
75
 90*


0.05
0.2
67
23
75
23


0.05
0.4
67
63
88
62


0.05
0.8
67
72
91
83


0.1
0.2
87
23
90
70


0.1
0.4
87
63
95
77


0.1
0.8
87
72
96
92


















TABLE 44








AVERAGE












DEAD IN %




PPM AI
(LARVAE)















Emamectin

Emamectin
EXPECTED
OBSERVED


A5
benzoate
A5
benzoate
MORTALITY
MORTALITY















0.025
0.0015
3
5
8
2 


0.025
0.003
3
5
8
15*


0.025
0.006
3
10
13
25*


0.05
0.0015
7
5
12
 3 


0.05
0.003
7
5
12
17*


0.05
0.006
7
10
16
27*


0.1
0.0015
30
5
34
67*


0.1
0.003
30
5
34
33 


0.1
0.006
30
10
37
57*



















TABLE 45









AVERAGE












DEAD IN %




PPM AI
(LARVAE)















Lambda

Lambda
EXPECTED
OBSERVED


A5
Cyhalothrin
A5
Cyhalothrin
MORTALITY
MORTALITY















0.025
0.05
6
33
37
 80*


0.025
0.1
6
100
100
100


0.025
0.2
6
100
100
100


0.05
0.05
27
33
51
 70*


0.05
0.1
27
100
100
100


0.05
0.2
27
100
100
100


0.1
0.05
66
33
77
 63


0.1
0.1
66
100
100
100


0.1
0.2
66
100
100
100



















TABLE 46









AVERAGE












DEAD IN %




PPM AI
(LARVAE)
EXPECTED
OBSERVED













Pymetro-

Pymetro-
MOR-
MOR-


A5
zine
A5
zine
TALITY
TALITY















0.025
200
10
37
43
13


0.05
200
47
37
67
45


0.1
200
73
37
83
67



















TABLE 47









AVERAGE












DEAD IN %




PPM AI
(LARVAE)















Spiro-

Spiro-
EXPECTED
OBSERVED


A5
tetramat
A5
tetramat
MORTALITY
MORTALITY















0.025
200
10
98
98
98


0.05
200
47
98
99
100*


0.1
200
73
98
99
100*



















TABLE 48









AVERAGE














DEAD IN %
EXPECTED
OBSERVED










PPM AI
(LARVAE)
MORTAL-
MORTAL-












A5
Thiamethoxam
A5
Thiamethoxam
ITY
ITY















0.025
200
10
80
82
 83*


0.05
200
47
80
89
85


0.1
200
73
80
95
82




















TABLE 49









AVERAGE DEAD












PPM Al
IN % (EGGS)















Lambda

Lambda
EXPECTED
OBSERVED


A1
Cyhalothrin
A1
Cyhalothrin
MORTALITY
MORTALITY















0.2
0.05
0
0
0
 3*


0.2
0.1
0
17
17
47*


0.2
0.2
0
50
50
73*


0.4
0.05
0
0
0
0


0.4
0.1
0
17
17
30*


0.4
0.2
0
50
50
80*


0.8
0.05
0
0
0
 3*


0.8
0.1
0
17
17
50*


0.8
0.2
0
50
50
77*




















TABLE 50









AVERAGE













DEAD IN




PPM Al
% (EGGS)















Spiro-

Spiro-
EXPECTED
OBSERVED


A1
tetramat
A1
tetramat
MORTALITY
MORTALITY















0.2
100
0
0
0
 0


0.2
200
0
67
67
100*


0.4
100
0
0
0
 0


0.4
200
0
67
67
67


0.8
100
0
0
0
 0


0.8
200
0
67
67
67




















TABLE 51









AVERAGE DEAD












PPM Al
IN % (EGGS)















Thia-

Thia-
EXPECTED
OBSERVED


A1
methoxam
A1
methoxam
MORTALITY
MORTALITY















0.2
100
0
0
0
0


0.2
200
0
0
0
0


0.4
100
0
0
0
0


0.4
200
0
0
0
0


0.8
100
0
0
0
27*


0.8
200
0
0
0
33*




















TABLE 52









AVERAGE













DEAD




PPM Al
IN % (EGGS)















Lambda

Lambda





Cyhalo-

Cyhalo-
EXPECTED
OBSERVED


A5
thrin
A5
thrin
MORTALITY
MORTALITY















0.025
0.05
0
0
0
0


0.025
0.1
0
17
17
47*


0.025
0.2
0
50
50
77*


0.05
0.05
0
0
0
0


0.05
0.1
0
17
17
40*


0.05
0.2
0
50
50
77*


0.1
0.05
0
0
0
0


0.1
0.1
0
17
17
30*


0.1
0.2
0
50
50
40 



















TABLE 53








AVERAGE DEAD




PPM Al
IN % (EGGS)















Spiro-

Spiro-
EXPECTED
OBSERVED


A5
tetramat
A5
tetramat
MORTALITY
MORTALITY















0.025
200
0
65
65
62 


0.05
200
0
65
65
92*


0.1
200
0
65
65
87*



















TABLE 54








AVERAGE DEAD




PPM Al
IN % (EGGS)















Thia-

Thia-
EXPECTED
OBSERVED


A5
methoxam
A5
methoxam
MORTALITY
MORTALITY





0.025
200
0
0
0
0


0.05
200
0
0
0
0


0.1
200
0
0
0
77*









Single compound applications or combinations of A1 or A5 with Abamectin, Chlorpyrifos, Cyantraniliprole, Emamectin benzoate, or Pymetrozine were all inactive on eggs.



Heliothis Virescens (Tobacco Budworm)

Eggs (0-24 h old) are placed in 24-well microtiter plate on artificial diet and treated with test solutions (DMSO) by pipetting. After an incubation period of 4 days, samples are checked for larval mortality. Application rates are as indicated in the Tables.













TABLE 55









AVERAGE












PPM Al
DEAD IN %















Floni-
SYN
Floni-
EXPECTED
OBSERVED


A5
camid
545706
camid
MORTALITY
MORTALITY















3.2
100
98
0
98
95


1.6
50
90
15
92
 98*


0.8
25
95
0
95
 98*


0.4
12.5
90
0
90
75


0.2
6.25
35

35
10


1.6
100
90
0
90
 95*


0.8
50
95
15
96
93


0.4
25
90
0
90
75


0.2
12.5
35
0
35
25


0.1
6.25
0

0
  5*


0.8
100
95
0
95
85


0.4
50
90
15
92
 93*


0.2
25
35
0
35
 0


0.8
200
95
0
95
 98*


0.4
100
90
0
90
 93*


0.2
50
35
15
45
 0


0.8
400
95
0
95
 98*


0.4
200
90
0
90
90


0.2
100
35
0
35
 0


0.1
50
0
15
15
 0




















TABLE 56









AVERAGE












PPM Al
DEAD IN %















Imida-
SYN
Imida-
EXPECTED
OBSERVED


A5
cloprid
545706
cloprid
MORTALITY
MORTALITY















3.2
50
96
85
99
93


1.6
25
91
75
98
95


0.8
12.5
88
0
88
85


0.4
6.25
78
0
78
 80*


0.2
3.125
25

25
 0


1.6
50
91
85
99
98


0.8
25
88
75
97
88


0.4
12.5
78
0
78
50


0.2
6.25
25
0
25
 0


0.8
50
88
85
98
100*


0.4
25
78
75
94
 95*


0.2
12.5
25
0
25
20


0.8
100
88
88
98
100 


0.4
50
78
85
97
93


0.2
25
25
75
81
60


0.1
12.5
0
0
0
 20*


0.8
200
88
100
100
100 


0.4
100
78
88
97
 98*


0.2
50
25
85
89
60


0.1
25
0
75
75
 5




















TABLE 57









AVERAGE












PPM Al
DEAD IN %















Clothia-
SYN
Clothia-
EXPECTED
OBSERVED


A5
nidin
545706
nidin
MORTALITY
MORTALITY















3.2
3
96
0
96
 98*


1.6
1.5
91
0
91
 93*


0.8
0.75
88
0
88
85


0.4
0.375
78
0
78
10


0.2
0.187
25

25
 0


1.6
3
91
0
91
85


0.8
1.5
88
0
88
85


0.4
0.75
78
0
78
70


0.2
0.375
25
0
25
 0


0.8
3
88
0
88
 98*


0.4
1.5
78
0
78
 88*


0.2
0.75
25
0
25
 0


0.8
6
88
45
93
93


0.4
3
78
0
78
 90*


0.2
1.5
25
0
25
 0


0.8
12
88
80
98
90


0.4
6
78
45
88
 90*


0.2
3
25
0
25
 0



















TABLE 58








AVERAGE




PPM Al
DEAD IN %















Aba-

Aba-
EXPECTED
OBSERVED


A6
mectin
A6
mectin
MORTALITY
MORTALITY















3.2
1.6
95
78
99
95


1.6
0.8
95
68
98
85


0.8
0.4
85
45
92
75


0.4
0.2
65
0
65
 85*


0.2
0.1
5

5
 0


1.6
1.6
95
78
99
95


0.8
0.8
85
68
95
85


0.4
0.4
65
45
81
35


0.2
0.2
5
0
5
 0


0.8
1.6
85
78
97
85


0.4
0.8
65
68
89
75


0.2
0.4
5
45
48
 55*


0.8
3.2
85
100
100
100 


0.4
1.6
65
78
92
90


0.2
0.8
5
68
69
60


0.1
0.4
0
45
45
35


0.8
6.4
85
100
100
100 


0.4
3.2
65
100
100
100 


0.2
1.6
5
78
79
60


0.1
0.8
0
68
68
 75*


0.05
0.4

45
45
 0



















TABLE 59








AVERAGE




PPM Al
DEAD IN %















Emamectin

Emamectin
EXPECTED
OBSERVED


A6
benzoate
A6
benzoate
MORTALITY
MORTALITY















3.2
0.006
100
0
100
95


1.6
0.003
90
0
90
90


0.8
0.0015
95
0
95
90


0.4
0.00075
70
0
70
45


0.2
0.000375
5

5
 0


1.6
0.006
90
0
90
90


0.8
0.003
95
0
95
85


0.4
0.0015
70
0
70
40


0.2
0.00075
5
0
5
 50*


0.8
0.006
95
0
95
90


0.4
0.003
70
0
70
60


0.2
0.0015
5
0
5
 0


0.8
0.012
95
55
98
90


0.4
0.006
70
0
70
 85*


0.2
0.003
5
0
5
 0


0.8
0.024
95
93
100
90


0.4
0.012
70
55
87
80


0.2
0.006
5
0
5
 0



















TABLE 60








AVERAGE




PPM Al
DEAD IN %















Chlor-

Chlor-
EXPECTED
OBSERVED


A6
pyrifos
A6
pyrifos
MORTALITY
MORTALITY















3.2
200
100
100
100
100


1.6
100
100
100
100
100


0.8
50
95
90
100
100


0.4
25
65
45
81
 65


1.6
200
100
100
100
100


0.8
100
95
100
100
100


0.4
50
65
90
97
 75


0.2
25
0
45
45
 65*


0.8
200
95
100
100
 95


0.4
100
65
100
100
100


0.2
50
0
90
90
 85


0.1
25
0
45
45
 0


0.8
400
95
100
100
100


0.4
200
65
100
100
100


0.2
100
0
100
100
100


0.1
50
0
90
90
 80


0.05
25

45
45
 25


0.8
800
95
100
100
100


0.4
400
65
100
100
100


0.2
200
0
100
100
100


0.1
100
0
100
100
100


0.05
50

90
90
 85


0.025
25

45
45
 0



















TABLE 61








AVERAGE




PPM Al
DEAD IN %















Cyan-

Cyan-
EXPECTED
OBSERVED


A6
traniliprole
A6
traniliprole
MORTALITY
MORTALITY















3.2
0.2
95
78
99
100*


1.6
0.1
95
45
97
90


0.8
0.05
85
0
85
 90*


0.4
0.025
80
0
80
50


0.2
0.0125
65

65
 0


1.6
0.2
95
78
99
90


0.8
0.1
85
45
92
90


0.4
0.05
80
0
80
 85*


0.2
0.025
65
0
65
25


0.8
0.2
85
78
97
95


0.4
0.1
80
45
89
85


0.2
0.05
65
0
65
25


0.8
0.4
85
90
99
95


0.4
0.2
80
78
96
90


0.2
0.1
65
45
81
65


0.1
0.05
0
0
0
 25*


0.8
0.8
85
100
100
100 


0.4
0.4
80
90
98
90


0.2
0.2
65
78
92
85


0.1
0.1
0
45
45
 65*




















TABLE 62









AVERAGE












PPM Al
DEAD IN %















Lambda

Lambda





Cyhalo-

Cyhalo-
EXPECTED
OBSERVED


A6
thrin
A6
thrin
MORTALITY
MORTALITY















3.2
0.05
100
0
100
95


1.6
0.025
95
0
95
90


0.8
0.0125
90
0
90
70


0.4
0.00625
85
0
85
65


0.2
0.0032
25

25
 0


1.6
0.05
95
0
95
100*


0.8
0.025
90
0
90
85


0.4
0.0125
85
0
85
40


0.2
0.00625
25
0
25
 0


0.8
0.05
90
0
90
85


0.4
0.025
85
0
85
85


0.2
0.0125
25
0
25
 0


0.8
0.1
90
25
93
80


0.4
0.05
85
0
85
65


0.2
0.025
25
0
25
 0


0.8
0.2
90
75
98
80


0.4
0.1
85
25
89
80


0.2
0.05
25
0
25
25



















TABLE 63








AVERAGE




PPM Al
DEAD IN %















Pyme-

Pyme-
EXPECTED
OBSERVED


A6
trozine
A6
trozine
MORTALITY
MORTALITY















3.2
200
98
0
98
93 


1.6
100
90
0
90
90 


0.8
50
75
0
75
90*


0.4
25
75
0
75
10 


1.6
200
90
0
90
88 


0.8
100
75
0
75
80*


0.4
50
75
0
75
85*


0.8
200
75
0
75
85*


0.4
100
75
0
75
85*


0.2
50
0
0
0
0


0.8
400
75
0
75
85*


0.4
200
75
0
75
80*


0.8
800
75
0
75
85*


0.4
400
75
0
75
85*



















TABLE 64








AVERAGE




PPM AI
DEAD IN %
EXPECTED
OBSERVED












A6
Spirotetramat
A6
Spirotetramat
MORTALITY
MORTALITY















3.2
50
98
0
98
95 


1.6
25
90
0
90
93*


0.8
12.5
90
0
90
90 


0.4
6.25
45
0
45
75*


0.2
3.125
 0

0
25*


1.6
50
90
0
90
93*


0.8
25
90
0
90
88 


0.4
12.5
45
0
45
25 


0.8
50
90
0
90
85 


0.4
25
45
0
45
80*


0.8
100
90
0
90
80 


0.4
50
45
0
45
85*


0.2
25
 0
0
0
 0 


0.1
12.5
 0
0
0
25*


0.8
200
90
0
90
90 


0.4
100
45
0
45
85*


0.2
50
 0
0
0
 0 


0.1
25
 0
0
0
25*



















TABLE 65








AVERAGE




PPM AI
DEAD IN %
EXPECTED
OBSERVED












A6
Thiamethoxam
A6
Thiamethoxam
MORTALITY
MORTALITY















3.2
50
95
0
95
95 


1.6
25
95
0
95
90 


0.8
12.5
85
0
85
85 


0.4
6.25
70
0
70
45 


0.2
3.125
35

35
10 


1.6
50
95
0
95
90 


0.8
25
85
0
85
90*


0.4
12.5
70
0
70
70 


0.2
6.25
35
0
35
25 


0.8
50
85
0
85
90*


0.4
25
70
0
70
90*


0.2
12.5
35
0
35
 0 


0.8
100
85
25
89
 0 


0.4
50
70
0
70
45 


0.2
25
35
0
35
 0 


0.8
200
85
65
95
85 


0.4
100
70
25
78
80*


0.2
50
35
0
35
 0 



















TABLE 66








AVERAGE




PPM AI
DEAD IN %
EXPECTED
OBSERVED












A6
Flonicamid
A6
Flonicamid
MORTALITY
MORTALITY















3.2
100
95
0
95
95 


1.6
50
90
0
90
95*


0.8
25
75
0
75
85*


0.4
12.5
65
0
65
70*


0.2
6.25
25

25
50*


1.6
100
90
0
90
90 


0.8
50
75
0
75
90*


0.4
25
65
0
65
55 


0.2
12.5
25
0
25
 0 


0.8
100
75
0
75
85*


0.4
50
65
0
65
85*


0.2
25
25
0
25
 0 


0.8
200
75
0
75
85*


0.4
100
65
0
65
85*


0.2
50
25
0
25
 0 


0.8
400
75
0
75
75 


0.4
200
65
0
65
80*


0.2
100
25
0
25
 0 




















TABLE 67









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A6
Imidacloprid
A6
Imidacloprid
MORTALITY
MORTALITY















3.2
50
100
50
100
100 


1.6
25
95
20
96
 93 


0.8
12.5
85
0
85
 45 


0.4
6.25
85
0
85
 0 


1.6
50
95
50
98
 95 


0.8
25
85
20
88
 88 


0.4
12.5
85
0
85
 25 


0.8
50
85
50
93
 90 


0.4
25
85
20
88
 75 


0.8
100
85
95
99
 93 


0.4
50
85
50
93
 93 


0.2
25
0
20
20
 0 


0.1
12.5
0
0
0
 5*


0.8
200
85
100
100
100 


0.4
100
85
95
99
 95 


0.2
50
0
50
50
 0 


0.1
25
0
20
20
 0 




















TABLE 68









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A6
Clothianidin
A6
Clothianidin
MORTALITY
MORTALITY















3.2
3
100
3
100
98 


1.6
1.5
 95
0
95
95 


0.8
0.75
 80
0
80
83*


0.4
0.375
 70
0
70
70 


0.2
0.187
 20

20
10 


1.6
3
 95
3
95
95 


0.8
1.5
 80
0
80
95*


0.4
0.75
 70
0
70
65 


0.2
0.375
 20
0
20
 0 


0.8
3
 80
3
81
80 


0.4
1.5
 70
0
70
80*


0.2
0.75
 20
0
20
 0 


0.8
6
 80
38
88
90*


0.4
3
 70
3
71
75*


0.2
1.5
 20
0
20
 0 


0.8
12
 80
48
90
90 


0.4
6
 70
38
81
85*


0.2
3
 20
3
22
 0 


0.1
1.5
 0
0
0
10*




















TABLE 69









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Abamectin
A8
Abamectin
MORTALITY
MORTALITY















3.2
1.6
100
78
100
 95 


1.6
0.8
90
68
97
 90 


0.8
0.4
90
45
95
 90 


0.4
0.2
85
0
85
 55 


0.2
0.1
65

65
 0 


1.6
1.6
90
78
98
 85 


0.8
0.8
90
68
97
 80 


0.4
0.4
85
45
92
 60 


0.2
0.2
65
0
65
 50 


0.8
1.6
90
78
98
 90 


0.4
0.8
85
68
95
 75 


0.2
0.4
65
45
81
 50 


0.1
0.2
0
0
0
 40*


0.8
3.2
90
100
100
 90 


0.4
1.6
85
78
97
 90 


0.2
0.8
65
68
89
 70 


0.1
0.4
0
45
45
 50*


0.8
6.4
90
100
100
100 


0.4
3.2
85
100
100
 95 


0.2
1.6
65
78
92
 85 


0.1
0.8
0
68
68
 40 


0.05
0.4

45
45
 0 




















TABLE 70









AVERAGE












PPM AI
DEAD IN %















Emamectin

Emamectin
EXPECTED
OBSERVED


A8
benzoate
A8
benzoate
MORTALITY
MORTALITY















3.2
0.006  
95
0
95
90 


1.6
0.003  
90
0
90
90 


0.8
0.0015 
90
0
90
90 


0.4
0.00075 
45
0
45
50*


1.6
0.006  
90
0
90
85 


0.8
0.003  
90
0
90
75 


0.4
0.0015 
45
0
45
45 


0.2
0.00075 
0
0
0
10*


0.1
0.000375
0

0
10*


0.8
0.006  
90
0
90
90 


0.4
0.003  
45
0
45
80*


0.8
0.012  
90
55
96
85 


0.4
0.006  
45
0
45
75*


0.8
0.024  
90
93
99
90 


0.4
0.012  
45
55
75
80*




















TABLE 71









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Chlorpyrifos
A8
Chlorpyrifos
MORTALITY
MORTALITY















3.2 
200
100
100
100
100 


1.6 
100
95
100
100
100 


0.8 
50
90
90
99
 95 


0.4 
25
65
45
81
 80 


0.2 
12.5
25

25
 25 


0.1 
6.25
0

0
 25*


1.6 
200
95
100
100
100 


0.8 
100
90
100
100
100 


0.4 
50
65
90
97
 70 


0.2 
25
25
45
59
 50 


0.8 
200
90
100
100
100 


0.4 
100
65
100
100
100 


0.2 
50
25
90
93
 90 


0.1 
25
0
45
45
 25 


0.8 
400
90
100
100
100 


0.4 
200
65
100
100
100 


0.2 
100
25
100
100
100 


0.1 
50
0
90
90
100*


0.05 
25

45
45
 0 


0.8 
800
90
100
100
100 


0.4 
400
65
100
100
100 


0.2 
200
25
100
100
 0 


0.1 
100
0
100
100
100 


0.05 
50

90
90
 65 


0.025
25

45
45
 0 




















TABLE 72









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Cyantraniliprole
A8
Cyantraniliprole
MORTALITY
MORTALITY















3.2
0.2
95
78
99
95 


1.6
0.1
90
45
95
90 


0.8
0.05
80
0
80
85*


0.4
0.025
65
0
65
65 


0.2
0.0125
50

50
 0 


1.6
0.2
90
78
98
95 


0.8
0.1
80
45
89
85 


0.4
0.05
65
0
65
65 


0.2
0.025
50
0
50
80*


0.8
0.2
80
78
96
90 


0.4
0.1
65
45
81
80 


0.2
0.05
50
0
50
 0 


0.8
0.4
80
90
98
90 


0.4
0.2
65
78
92
80 


0.2
0.1
50
45
73
25 


0.1
0.05
 0
0
0
65*


0.8
0.8
80
100
100
90 


0.4
0.4
65
90
97
85 


0.2
0.2
50
78
89
80 


0.1
0.1
 0
45
45
60*




















TABLE 73









AVERAGE












PPM AI
DEAD IN %















Lambda

Lambda
EXPECTED
OBSERVED


A8
Cyhalothrin
A8
Cyhalothrin
MORTALITY
MORTALITY















3.2
0.05
95
0
95
100*


1.6
0.025
90
0
90
 95*


0.8
0.0125
85
0
85
 90*


0.4
0.00625
75
0
75
 75 


0.2
0.0032
35

35
 0 


1.6
0.05
90
0
90
 90 


0.8
0.025
85
0
85
 80 


0.4
0.0125
75
0
75
 25 


0.2
0.00625
35
0
35
 25 


0.8
0.05
85
0
85
 90*


0.4
0.025
75
0
75
 75 


0.2
0.0125
35
0
35
 40*


0.8
0.1
85
25
89
 85 


0.4
0.05
75
0
75
 80*


0.2
0.025
35
0
35
 0 


0.8
0.2
85
75
96
 75 


0.4
0.1
75
25
81
 50 


0.2
0.05
35
0
35
 0 




















TABLE 74









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Pymetrozine
A8
Pymetrozine
MORTALITY
MORTALITY















3.2
200
93
0
93
93 


1.6
100
90
0
90
90 


0.8
50
85
0
85
75 


0.4
25
65
0
65
55 


0.2
12.5
50

50
 0 


1.6
200
90
0
90
90 


0.8
100
85
0
85
85 


0.4
50
65
0
65
60 


0.2
25
50
0
50
 0 


0.8
200
85
0
85
90*


0.4
100
65
0
65
85*


0.2
50
50
0
50
 0 


0.8
400
85
0
85
85 


0.4
200
65
0
65
80*


0.2
100
50
0
50
 0 


0.8
800
85
0
85
85 


0.4
400
65
0
65
75*


0.2
200
50
0
50
 0 


0.1
100
 0
0
0
25*




















TABLE 75









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Spirotetramat
A8
Spirotetramat
MORTALITY
MORTALITY















3.2
50
100
0
100
98 


1.6
25
 93
0
93
93 


0.8
12.5
 90
0
90
85 


0.4
6.25
 25
0
25
 0 


1.6
50
 93
0
93
90 


0.8
25
 90
0
90
90 


0.4
12.5
 25
0
25
45*


0.8
50
 90
0
90
90 


0.4
25
 25
0
25
90*


0.8
100
 90
0
90
88 


0.4
50
 25
0
25
85*


0.8
200
 90
0
90
90 


0.4
100
 25
0
25
80*




















TABLE 76









AVERAGE
EXPECTED
OBSERVED










PPM AI
DEAD IN %
MOR-
MOR-












A8
Thiamethoxam
A8
Thiamethoxam
TALITY
TALITY















3.2 
50
95
0
95
100*


1.6 
25
90
0
90
 90 


0.8 
12.5
90
0
90
 85 


0.4 
6.25
75
0
75
 40 


0.2 
3.125
55

55
 10 


0.1 
1.563
 0

0
 0 


1.6 
50
90
0
90
 90 


0.8 
25
90
0
90
 85 


0.4 
12.5
75
0
75
 90*


0.2 
6.25
55
0
55
 50 


0.8 
50
90
0
90
 90 


0.4 
25
75
0
75
 75 


0.2 
12.5
55
0
55
 0 


0.025
1.563


0
 0 


0.8 
100
90
25
93
 85 


0.4 
50
75
0
75
 85*


0.2 
25
55
0
55
 0 


0.8 
200
90
65
97
 95 


0.4 
100
75
25
81
 80 


0.2 
50
55
0
55
 0 


0.1 
25
 0
0
0
 40*

























AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Flonicamid
A8
Flonicamid
MORTALITY
MORTALITY















3.2
100
95
0
95
93 


1.6
50
93
0
93
90 


0.8
25
85
0
85
85 


0.4
12.5
60
0
60
50 


1.6
100
93
0
93
93 


0.8
50
85
0
85
90*


0.4
25
60
0
60
70*


0.8
100
85
0
85
95*


0.4
50
60
0
60
93*


0.8
200
85
0
85
98*


0.4
100
60
0
60
90*


0.8
400
85
0
85
93*


0.4
200
60
0
60
85*




















TABLE 78









AVERAGE












PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Imidacloprid
A8
Imidacloprid
MORTALITY
MORTALITY















3.2
50
100
50
100
 95 


1.6
25
 95
20
96
 93 


0.8
12.5
 90
0
90
 70 


0.4
6.25
 60
0
60
 60 


1.6
50
 95
50
98
 93 


0.8
25
 90
20
92
 88 


0.4
12.5
 60
0
60
 30 


0.8
50
 90
50
95
 93 


0.4
25
 60
20
68
 85*


0.2
12.5
 0
0
0
 20*


0.8
100
 90
95
100
 98 


0.4
50
 60
50
80
 90*


0.2
25
 0
20
20
 10 


0.1
12.5
 0
0
0
 15*


0.8
200
 90
100
100
100 


0.4
100
 60
95
98
 85 


0.2
50
 0
50
50
 35 


0.1
25
 0
20
20
 25*



















TABLE 79








AVERAGE




PPM AI
DEAD IN %
EXPECTED
OBSERVED












A8
Clothianidin
A8
Clothianidin
MORTALITY
MORTALITY















3.2
3
98
3
98
100*


1.6
1.5
95
0
95
95


0.8
0.75
98
0
98
93


0.4
0.375
60
0
60
 65*


1.6
3
95
3
95
93


0.8
1.5
98
0
98
95


0.4
0.75
60
0
60
60


0.8
3
98
3
98
93


0.4
1.5
60
0
60
 85*


0.2
0.75
0
0
0
 10*


0.8
6
98
38
98
93


0.4
3
60
3
61
 95*


0.2
1.5
0
0
0
 20*


0.1
0.75
0
0
0
 45*


0.8
12
98
48
99
95










Tetranychus Urticae (Two Spotted Spider Mite)

(Contact/Feeding Activity)

Bean plants are infested with mite populations of mixed ages. 1 day after infestation, plants are treated in a spray chamber with diluted test solutions. 1 and 8 days later, samples are checked for adult mortality. 2 replicates per treatment were evaluated. Application rates are as indicated in the Tables.













TABLE 80









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A1
Abamectin
A1
Abamectin
MORTALITY
MORTALITY















1.6
0.0015
0
0
0
 0


1.6
0.003
0
0
0
 0


1.6
0.006
0
0
0
 10*


3.125
0.0015
0
0
0
 0


3.125
0.003
0
0
0
 20*


3.125
0.006
0
0
0
 25*


6.25
0.0015
40
0
40
25


6.25
0.003
40
0
40
10


6.25
0.006
40
0
40
30




















TABLE 81









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A1
Chlorpyrifos
A1
Chlorpyrifos
MORTALITY
MORTALITY















1.6
50
0
0
0
 30*


1.6
100
0
60
60
100*


1.6
200
0
88
88
100*


3.125
50
20
0
20
 75*


3.125
100
40
60
76
 95*


3.125
200
40
88
93
100*


6.25
50
50
0
50
 70*


6.25
100
80
60
92
100*


6.25
200
80
88
98
95




















TABLE 82









AVERAGE
EX-
OB-











DEAD IN %
PECTED
SERVED


PPM AI
AFTER 1 DAY
MORTAL-
MORTAL-












A1
Cyantraniliprole
A1
Cyantraniliprole
ITY
ITY





1.6 
100
 0
 0
 0
30*


1.6 
200
 0
10
10
55*


3.125
100
20
 0
20
60*


3.125
200
20
10
28
65*


6.25 
100
50
 0
50
85*


6.25 
200
50
10
55
80*




















TABLE 83









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY















Emamectin

Emamectin
EXPECTED
OBSERVED


A1
benzoate
A1
benzoate
MORTALITY
MORTALITY















1.6
0.0125
0
0
0
 0


1.6
0.025
0
8
8
 0


1.6
0.05
0
0
0
 10*


3.125
0.0125
45
0
45
40


3.125
0.025
45
8
49
 50*


3.125
0.05
45
0
45
45


6.25
0.0125
80
0
80
 90*


6.25
0.025
80
8
82
 95*


6.25
0.05
80
0
80
100*




















TABLE 84









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY















Lambda

Lambda
EXPECTED
OBSERVED


A1
Cyhalothrin
A1
Cyhalothrin
MORTALITY
MORTALITY















1.6
3.125
0
25
25
15


1.6
6.25
0
55
55
50


1.6
12.5
0
88
88
100*


3.125
3.125
10
25
33
 80*


3.125
6.25
10
55
60
100*


3.125
12.5
10
88
89
 95*


6.25
3.125
80
25
85
 95*


6.25
6.25
80
55
91
100*


6.25
12.5
80
88
98
100*




















TABLE 85









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A1
Pymetrozine
A1
Pymetrozine
MORTALITY
MORTALITY















1.6
200
0
5
5
0


3.125
200
40
5
43
40


6.25
200
80
5
81
80




















TABLE 86









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A1
Spirotetramat
A1
Spirotetramat
MORTALITY
MORTALITY















1.6
0.1
0
13
13
10


1.6
0.2
0
18
18
 35*


1.6
0.4
0
23
23
 35*


3.125
0.1
15
13
26
20


3.125
0.2
15
18
30
10


3.125
0.4
15
23
35
25


6.25
0.1
75
13
78
 90*


6.25
0.2
75
18
80
 95*


6.25
0.4
75
23
81
 85*




















TABLE 87









AVERAGE
EX-
OB-











DEAD IN %
PECTED
SERVED


PPM AI
AFTER 1 DAY
MORTAL-
MORTAL-












A1
Thiamethoxam
A1
Thiamethoxam
ITY
ITY





1.6 
200
 0
0
 0
35


3.125
200
40
0
40
15


6.25 
200
80
0
80
100 




















TABLE 88









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A5
Abamectin
A5
Abamectin
MORTALITY
MORTALITY















0.4
0.0015
0
0
0
 0


0.4
0.003
0
0
0
 10*


0.4
0.006
0
0
0
 20*


0.8
0.0015
20
0
20
 0


0.8
0.003
20
0
20
 0


0.8
0.006
20
0
20
 25*


1.6
0.0015
80
0
80
15


1.6
0.003
80
0
80
45


1.6
0.006
80
0
80
30




















TABLE 89









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A5
Chlorpyrifos
A5
Chlorpyrifos
MORTALITY
MORTALITY















0.4
50
0
0
0
10


0.4
100
0
60
60
60


0.4
200
0
88
88
100*


0.8
50
30
0
30
 40*


0.8
100
0
60
60
100*


0.8
200
0
88
88
 95*


1.6
50
30
0
30
 80*


1.6
100
75
60
90
 95*


1.6
200
75
88
97
95




















TABLE 90









AVERAGE
EX-
OB-











DEAD IN %
PECTED
SERVED


PPM AI
AFTER 1 DAY
MORTAL-
MORTAL-












A5
Cyantraniliprole
A5
Cyantraniliprole
ITY
ITY





0.4
100
 0
 0
 0
70*


0.4
200
 0
10
10
70*


0.8
100
30
 0
30
50*


0.8
200
30
10
37
60*


1.6
100
30
 0
30
55*


1.6
200
30
10
37
80*




















TABLE 91









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY















Emamectin

Emamectin
EXPECTED
OBSERVED


A5
benzoate
A5
benzoate
MORTALITY
MORTALITY















0.4
0.0125
0
0
0
 0


0.4
0.025
0
8
8
 0


0.4
0.05
0
0
0
 20*


0.8
0.0125
15
0
15
 20*


0.8
0.025
15
8
22
 30*


0.8
0.05
15
0
15
 25*


1.6
0.0125
65
0
65
40


1.6
0.025
65
8
68
55


1.6
0.05
65
0
65
 85*




















TABLE 92









AVERAGE






DEAD IN %
EX-
OB-










PPM AI
AFTER 1 DAY
PECTED
SERVED













Lambda

Lambda
MORTAL-
MORTAL-


A5
Cyhalothrin
A5
Cyhalothrin
ITY
ITY















0.4
3.125
10
25
33
15


0.4
6.25
10
55
60
60


0.4
12.5
10
88
89
95*


0.8
3.125
35
25
51
 80*


0.8
6.25
35
55
71
 80*


0.8
12.5
35
88
92
100*


1.6
3.125
75
25
81
45


1.6
6.25
75
55
89
75


1.6
12.5
75
88
97
100*




















TABLE 93









AVERAGE













DEAD IN %




PPM AI
AFTER 1 DAY
EXPECTED
OBSERVED












A5
Pymetrozine
A5
Pymetrozine
MORTALITY
MORTALITY















0.4
200
0
5
5
0


0.8
200
0
5
5
 35*


1.6
200
75
5
76
70



















TABLE 94








AVERAGE





DEAD IN %




PPM Al
AFTER 1 DAY
EXPECTED
OBSERVED












A5
Spirotetramat
A5
Spirotetramat
MORTALITY
MORTALITY















0.4
0.1
0
13
13
10


0.4
0.2
0
18
18
10


0.4
0.4
0
23
23
15


0.8
0.1
0
13
13
10


0.8
0.2
0
18
18
 25*


0.8
0.4
0
23
23
 40*


1.6
0.1
10
13
22
10


1.6
0.2
10
18
26
 35*


1.6
0.4
10
23
31
25



















TABLE 95








AVERAGE





DEAD IN %
EXPECTED
OBSERVED


PPM Al
AFTER 1 DAY
MORTAL-
MORTAL-












A5
Thiamethoxam
A5
Thiamethoxam
ITY
ITY















0.4
200
0
0
0
0


0.8
200
0
0
0
40*


1.6
200
75
0
75
65 



















TABLE 96








AVERAGE





DEAD IN %




PPM Al
AFTER 1 DAY
EXPECTED
OBSERVED













Lambda

Lambda
MORTAL-
MORTAL-


A6
Cyhalothrin
A6
Cyhalothrin
ITY
ITY















0.2
3.125
3
70
71
100*


0.2
6.25
3
90
90
100*


0.2
12.5
3
83
84
100*


0.4
3.125
20
70
76
100*


0.4
6.25
20
90
92
100*


0.4
12.5
20
83
86
100*


0.8
3.125
85
70
96
90


0.8
6.25
85
90
99
100*


0.8
12.5
85
83
97
100*



















TABLE 97








AVERAGE DEAD IN %

OB-


PPM Al
AFTER 1 DAY
EXPECTED
SERVED













Lambda

Lambda
MORTAL-
MORTAL-


A8
Cyhalothrin
A8
Cyhalothrin
ITY
ITY















0.4
3.125
38
70
81
 95*


0.4
6.25
38
90
94
100*


0.4
12.5
38
83
89
100*


0.8
3.125
35
70
81
 90*


0.8
6.25
35
90
94
85


0.8
12.5
35
83
89
85


1.5
3.125
100
70
100
90


1.5
6.25
100
90
100
95


1.5
12.5
100
83
100
95



















TABLE 98








AVERAGE





DEAD IN %
EXPECTED
OBSERVED


PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A1
Abamectin
A1
Abamectin
ITY
ITY















1.5
0.0015
30
25
48
35


1.5
0.003
30
20
44
30


1.5
0.006
30
25
48
35


3.125
0.0015
45
25
59
 70*


3.125
0.003
45
20
56
 75*


3.125
0.006
45
25
59
 75*


6.25
0.0015
65
25
74
100*


6.25
0.003
65
20
72
100*


6.25
0.006
65
25
74
100*



















TABLE 99








AVERAGE
EXPECT-
OBSERV-



DEAD IN %
ED
ED


PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A1
Chlorpyrifos
A1
Chlorpyrifos
ITY
ITY















1.5
50
30
0
30
 65*


1.5
100
10
20
28
 80*


1.5
200
10
63
67
 75*


3.125
50
85
0
85
100*


3.125
100
60
20
68
 95*


3.125
200
60
63
85
 95*


6.25
50
90
0
90
 95*


6.25
100
90
20
92
100*


6.25
200
90
63
96
100*



















TABLE 100








AVERAGE
EXPECT-
OBSERV-



DEAD IN %
ED
ED


PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A1
Cyantraniliprole
A1
Cyantraniliprole
ITY
ITY















1.5
100
30
35
55
 75*


1.5
200
30
25
48
 85*


3.125
100
85
35
90
100*


3.125
200
85
25
89
80


6.25
100
90
35
94
 95*


6.25
200
90
25
93
100*



















TABLE 101








AVERAGE





DEAD IN %

OBSERV-


PPM Al
AFTER 8 DAYS
EXPECTED
ED













Emamectin

Emamectin
MORTAL-
MORTAL-


A1
benzoate
A1
benzoate
ITY
ITY















1.5
0.0125
30
5
34
 40*


1.5
0.025
30
23
46
40


1.5
0.05
30
38
57
 80*


3.125
0.0125
85
5
86
100*


3.125
0.025
85
23
88
100*


3.125
0.05
85
38
91
 95*


6.25
0.0125
95
5
95
100*


6.25
0.025
95
23
96
100*


6.25
0.05
95
38
97
100*



















TABLE 102








AVERAGE





DEAD IN %




PPM Al
AFTER 8 DAYS
EXPECTED
OBSERVED













Lambda

Lambda
MORTAL-
MORTAL-


A1
Cyhalothrin
A1
Cyhalothrin
ITY
ITY















1.5
3.125
10
20
28
20


1.5
6.25
10
85
87
80


1.5
12.5
10
98
98
100*


3.125
3.125
45
20
56
 95*


3.125
6.25
45
85
92
100*


3.125
12.5
45
98
99
100*


6.25
3.125
85
20
88
 95*


6.25
6.25
85
85
98
100*


6.25
12.5
85
98
100
100 



















TABLE 103








AVERAGE





DEAD IN %

OBSERVED


PPM Al
AFTER 8 DAYS
EXPECTED
MORTAL-












A1
Pymetrozine
A1
Pymetrozine
MORTALITY
ITY















1.5
200
10
0
10
50*


3.125
200
60
0
60
60 


6.25
200
90
0
90
95*



















TABLE 104








AVERAGE





DEAD IN %
EXPECTED
OBSERVED


PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A1
Spirotetramat
A1
Spirotetramat
ITY
ITY















1.5
0.1
0
10
10
  5


1.5
0.2
0
33
33
  65*


1.5
0.4
0
38
38
  75*


3.125
0.1
90
10
91
  95*


3.125
0.2
90
33
93
 100*


3.125
0.4
90
38
94
 100*


6.25
0.1
100
10
100
100


6.25
0.2
100
33
100
100


6.25
0.4
100
38
100
100



















TABLE 105








AVERAGE
EXPECT-
OBSERV-



DEAD IN %
ED
ED


PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A1
Thiamethoxam
A1
Thiamethoxam
ITY
ITY















1.5
200
10
5
15
 35*


3.125
200
60
5
62
 70*


6.25
200
90
5
91
100*



















TABLE 106








AVERAGE





DEAD IN %




PPM Al
AFTER 8 DAYS
EXPECTED
OBSERVED












A5
Abamectin
A5
Abamectin
MORTALITY
MORTALITY















0.4
0.0015
45
25
59
30


0.4
0.003
45
20
56
35


0.4
0.006
45
25
59
40


0.8
0.0015
80
25
85
35


0.8
0.003
80
20
84
55


0.8
0.006
80
25
85
75


1.5
0.0015
100
25
100
100


1.5
0.003
100
20
100
95


1.5
0.006
100
25
100
100




















TABLE 107









AVERAGE






DEAD IN %
EXPECTED
OBSERVED










PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A5
Chlorpyrifos
A5
Chlorpyrifos
ITY
ITY















0.4
50
25
0
25
 55*


0.4
100
0
20
20
 40*


0.4
200
0
63
63
 65*


0.8
50
65
0
65
 75*


0.8
100
25
20
40
 80*


0.8
200
25
63
72
 85*


1.5
50
100
0
100
100


1.5
100
100
20
100
100


1.5
200
100
63
100
100



















TABLE 108








AVERAGE





DEAD IN %
EXPECTED
OBSERVED


PPM Al
AFTER 8 DAYS
MORTAL-
MORTAL-












A5
Cyantraniliprole
A5
Cyantraniliprole
ITY
ITY















0.4
100
25
35
51
 100*


0.4
200
25
25
44
 90*


0.8
100
65
35
77
 80*


0.8
200
65
25
74
 85*


1.5
100
100
35
100
100


1.5
200
100
25
100
100



















TABLE 109








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS















Emamectin

Emamectin
EXPECTED
OBSERVED


A5
benzoate
A5
benzoate
MORTALITY
MORTALITY















0.4
0.0125
15
5
19
 5


0.4
0.025
15
23
35
 10


0.4
0.05
15
38
47
 25


0.8
0.0125
55
5
57
 85*


0.8
0.025
55
23
65
 95*


0.8
0.05
55
38
72
 80*


1.5
0.0125
100
5
100
100


1.5
0.025
100
23
100
100


1.5
0.05
100
38
100
100



















TABLE 110








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS















Lambda

Lambda
EXPECTED
OBSERVED


A5
Cyhalothrin
A5
Cyhalothrin
MORTALITY
MORTALITY















0.4
3.125
0
20
20
 10


0.4
6.25
0
85
85
 60


0.4
12.5
0
98
98
100


0.8
3.125
40
20
52
 30


0.8
6.25
40
85
91
 50


0.8
12.5
40
98
99
 100*


1.5
3.125
100
20
100
100


1.5
6.25
100
85
100
100


1.5
12.5
100
98
100
100



















TABLE 111








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS
EXPECTED
OBSERVED












A5
Pymetrozine
A5
Pymetrozine
MORTALITY
MORTALITY





0.4
200
0
0
0
 15*


0.8
200
25
0
25
 35*


1.5
200
100
0
100
100



















TABLE 112








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS
EXPECTED
OBSERVED












A5
Spirotetramat
A5
Spirotetramat
MORTALITY
MORTALITY















0.4
0.1
0
10
10
 0


0.4
0.2
0
33
33
 0


0.4
0.4
0
38
38
 35


0.8
0.1
35
10
42
 95*


0.8
0.2
35
33
56
 95*


0.8
0.4
35
38
60
 100*


1.5
0.1
100
10
100
100


1.5
0.2
100
33
100
100


1.5
0.4
100
38
100
100



















TABLE 113








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS
EXPECTED
OBSERVED












A5
Thiamethoxam
A5
Thiamethoxam
MORTALITY
MORTALITY





0.4
200
0
5
5
 0


0.8
200
25
5
29
 40*


1.5
200
100
5
100
100



















TABLE 114








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS















Lambda

Lambda
EXPECTED
OBSERVED


A6
Cyhalothrin
A6
Cyhalothrin
MORTALITY
MORTALITY















0.2
3.125
3
75
76
100*


0.2
6.25
3
90
90
100*


0.2
12.5
3
90
90
100*


0.4
3.125
60
75
90
100*


0.4
6.25
60
90
96
100*


0.4
12.5
60
90
96
100*


0.8
3.125
85
75
96
100*


0.8
6.25
85
90
99
100*


0.8
12.5
85
90
99
100*



















TABLE 115








AVERAGE





DEAD IN %




PPM A1
AFTER 8 DAYS















Lambda

Lambda
EXPECTED
OBSERVED


A8
Cyhalothrin
A8
Cyhalothrin
MORTALITY
MORTALITY















0.4
3.125
55
75
89
100*


0.4
6.25
55
90
96
100*


0.4
12.5
55
90
96
100*


0.8
3.125
38
75
85
100*


0.8
6.25
38
90
94
100*


0.8
12.5
38
90
94
100*


1.5
3.125
100
75
100
100 


1.5
6.25
100
90
100
100 


1.5
12.5
100
90
100
100 










Tetranychus Urticae (Two-Spotted Spider Mite)

Bean leaf discs on agar in 24-well microtiter plates are sprayed with test solutions (DMSO). After drying, the leaf discs are infested with mite populations of mixed ages. 8 days later, discs are checked for mixed population mortality. Application rates are as indicated in the Tables.












TABLE 116








AVERAGE




PPM A1
DEAD IN %
EXPECTED
OBSERVED












A6
Abamectin
A6
Abamectin
MORTALITY
MORTALITY















0.4
0.1
90
85
99
100*


0.4
0.05
90
85
99
100*


0.4
0.025
90
0
90
100*


0.4
0.0125
90
0
90
100*


0.4
0.006
90
0
90
90


0.4
0.003
90
0
90
100*


0.4
0.0015
90
0
90
100*


0.4
0.0008
90
0
90
100*


0.4
0.0004
90
0
90
100*


0.4
0.0002
90
0
90
100*


0.2
0.1
0
85
85
 95*


0.2
0.05
0
85
85
100*


0.2
0.025
0
0
0
 90*


0.2
0.0125
0
0
0
 90*


0.2
0.006
0
0
0
 80*


0.2
0.003
0
0
0
 90*


0.2
0.0015
0
0
0
 90*


0.2
0.0008
0
0
0
 90*


0.2
0.0004
0
0
0
 70*


0.2
0.0002
0
0
0
 75*


0.1
0.1
0
85
85
 90*


0.1
0.05
0
85
85
80


0.05
0.1
0
85
85
45


0.05
0.05
0
85
85
40



















TABLE 117








AVERAGE




PPM A1
DEAD IN %
EXPECTED
OBSERVED












A6
Emamectin
A6
Emamectin
MORTALITY
MORTALITY















0.8
0.8
100
95
100
95


0.4
0.4
75
93
98
85


0.2
0.2
25
75
81
65


0.1
0.1
0
70
70
65


0.4
0.8
75
95
99
100*


0.2
0.4
25
93
94
 95*


0.1
0.2
0
75
75
75


0.05
0.1
0
70
70
25


0.2
0.8
25
95
96
100*


0.1
0.4
0
93
93
100*


0.05
0.2
0
75
75
60


0.025
0.1
0
70
70
25


0.2
1.6
25
95
96
100*


0.1
0.8
0
95
95
100*


0.05
0.4
0
93
93
75


0.025
0.2
0
75
75
 90*


0.0125
0.1

70
70
65


0.2
3.2
25
100
100
100 


0.1
1.6
0
95
95
100*


0.05
0.8
0
95
95
95


0.025
0.4
0
93
93
90


0.0125
0.2

75
75
60


0.00625
0.1

70
70
 0



















TABLE 118









EX-
OB-



AVERAGE
PECTED
SERVED


PPM A1
DEAD IN %
MOR-
MOR-












A6
Thiamethoxam
A6
Thiamethoxam
TALITY
TALITY















0.8
200
95
0
95
100* 


0.4
100
90
38
94
100* 


0.2
50
0
13
13
65*


0.1
25
25
0
25
0


0.4
200
90
0
90
85 


0.2
100
0
38
38
65*


0.1
50
25
13
34
0


0.2
200
0
0
0
80*


0.1
100
25
38
53
25 


0.05
50
0
13
13
0


0.025
25
0
0
0
25*


0.2
400
0
0
0
70*


0.1
200
25
0
25
30*


0.05
100
0
38
38
25 


0.025
50
0
13
13
0


0.2
800
0
13
13
65*


0.1
400
25
0
25
25 


0.05
200
0
0
0
0


0.025
100
0
38
38
25 


0.0125
50

13
13
0



















TABLE 119









EX-
OB-



AVERAGE
PECTED
SERVED


PPM A1
DEAD IN %
MOR-
MOR-












A6
Imidacloprid
A6
Imidacloprid
TALITY
TALITY















0.8
200
100
0
100
95


0.4
100
95
25
96
50


0.2
50
50
0
50
 0


0.1
25
50
0
50
50


0.05
12.5
25

25
25


0.4
200
95
0
95
80


0.2
100
50
25
63
 0


0.1
50
50
0
50
 0


0.05
25
25
0
25
 0


0.2
200
50
0
50
 80*


0.1
100
50
25
63
25


0.05
50
25
0
25
 0


0.2
400
50
13
56
 70*


0.1
200
50
0
50
 65*


0.05
100
25
25
44
 0


0.025
50
0
0
0
 60*


0.0125
25

0
0
 25*


0.2
800
50
25
63
 70*


0.1
400
50
13
56
25


0.05
200
25
0
25
 0


0.025
100
0
25
25
 50*



















TABLE 120








AVERAGE




PPM A1
DEAD IN %
EXPECTED
OBSERVED












A8
Abamectin
A8
Abamectin
MORTALITY
MORTALITY















0.4
0.1
80
80
96
90


0.4
0.05
80
70
94
90


0.4
0.025
80
0
80
100*


0.4
0.0125
80
0
80
100*


0.4
0.006
80
0
80
100*


0.4
0.003
80
0
80
100*


0.4
0.0015
80
0
80
100*


0.4
0.0008
80
0
80
100*


0.4
0.0004
80
0
80
100*


0.4
0.0002
80
0
80
100*


0.2
0.1
0
80
80
80


0.2
0.05
0
70
70
 85*


0.2
0.025
0
0
0
 80*


0.2
0.0125
0
0
0
100*


0.2
0.006
0
0
0
100*


0.2
0.003
0
0
0
 90*


0.2
0.0015
0
0
0
 90*


0.2
0.0008
0
0
0
 90*


0.2
0.0004
0
0
0
 90*


0.2
0.0002
0
0
0
 90*


0.1
0.1
0
80
80
 95*


0.1
0.05
0
70
70
 80*


0.05
0.1
0
80
80
55


0.05
0.05
0
70
70
 0



















TABLE 121








AVERAGE




PPM A1
DEAD IN %
EXPECTED
OBSERVED












A8
Emamectin
A8
Emamectin
MORTALITY
MORTALITY















0.8
0.8
100
95
100
90


0.4
0.4
65
93
97
90


0.2
0.2
50
75
88
30


0.1
0.1
50
70
85
 0


0.4
0.8
65
95
98
95


0.2
0.4
50
93
96
95


0.1
0.2
50
75
88
25


0.05
0.1
0
70
70
 0


0.2
0.8
50
95
98
95


0.1
0.4
50
93
96
95


0.05
0.2
0
75
75
 85*


0.025
0.1
0
70
70
 0


0.2
1.6
50
95
98
100*


0.1
0.8
50
95
98
95


0.05
0.4
0
93
93
100*


0.025
0.2
0
75
75
 95*


0.0125
0.1

70
70
65


0.2
3.2
50
100
100
100 


0.1
1.6
50
95
98
95


0.05
0.8
0
95
95
100*


0.025
0.4
0
93
93
100*


0.0125
0.2

75
75
 80*


0.00625
0.1

70
70
 0



















TABLE 122









EX-
OB-



AVERAGE
PECTED
SERVED


PPM A1
DEAD IN %
MOR-
MOR-












A8
Thiamethoxam
A8
Thiamethoxam
TALITY
TALITY















0.8
200
100
0
100
90 


0.4
100
85
38
91
85 


0.2
50
55
13
61
80*


0.1
25
50
0
50
0


0.4
200
85
0
85
65 


0.2
100
55
38
72
25 


0.1
50
50
13
56
0


0.2
200
55
0
55
65*


0.1
100
50
38
69
0


0.05
50
0
13
13
0


0.025
25
0
0
0
40*


0.2
400
55
0
55
90*


0.1
200
50
0
50
25 


0.05
100
0
38
38
0


0.025
50
0
13
13
25*


0.2
800
55
13
61
0


0.1
400
50
0
50
0


0.025
100
0
38
38
0


0.0125
50

13
13
0



















TABLE 123









EX-
OB-



AVERAGE
PECTED
SERVED


PPM A1
DEAD IN %
MOR-
MOR-












A8
Imidacloprid
A8
Imidacloprid
TALITY
TALITY















0.8
200
90
0
90
100*


0.4
100
85
25
89
85


0.2
50
80
0
80
 0


0.1
25
65
0
65
50


0.05
12.5
25

25
 0


0.4
200
85
0
85
80


0.2
100
80
25
85
60


0.1
50
65
0
65
25


0.05
25
25
0
25
 50*


0.2
200
80
0
80
75


0.1
100
65
25
74
60


0.05
50
25
0
25
25


0.2
400
80
13
83
 85*


0.1
200
65
0
65
65


0.05
100
25
25
44
 0


0.025
50
0
0
 0
 50*


0.0125
25

0
 0
 50*


0.2
800
80
25
85
50


0.1
400
65
13
69
50


0.05
200
25
0
25
 0


0.025
100
0
25
25
 50*


0.0125
50

0
 0
 25*









Unless otherwise indicated, the compounds were formulated as follows: Compound A1 EC, Compound A5 EC, Abamectin EC, Chlorpyrifos ME, Cyantraniliprole SC, Emamectin benzoate SG, Lambda-Cyhalothrin EC, Pymetrozine WP, Spirotetramat OD, Thiamethoxam WG. Data is not shown for experiments where there was no insect mortality.

Claims
  • 1. A pesticidal mixture comprising a component A and a component B, wherein component A is a compound of formula I
  • 2. A pesticidal mixture according to claim 1, wherein in the compound of formula I L is a direct bond or methylene; one of Y1 and Y2 is S and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.
  • 3. A pesticidal mixture according to claim 1, wherein in the compound of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.
  • 4. A pesticidal mixture according to claim 3, wherein the molar proportion of the cis SO compounds of formula I compared to the total amount of cis SO and trans SO compounds of formula I is greater than 50%.
  • 5. A pesticidal mixture according to claim 1, wherein in the compound of formula I L is a direct bond or methylene; one of Y1 and Y2 is SO2 and the other is CH2; A1 and A2 are C—H; R1 is hydrogen or methyl; R2 is trifluoromethyl; R3 is 3,5-dichloro-phenyl; R4 is methyl; and R5 is hydrogen.
  • 6. A pesticidal mixture according to claim 1, wherein when L is a direct bond Y2 is CH2 and Y1 is S, SO or SO2, and wherein when L is methylene Y2 is S, SO or SO2 and Y1 is CH2.
  • 7. A pesticidal mixture according to claim 1, wherein component A is a mixture of compounds I* and I**
  • 8. A pesticidal mixture according to claim 1, wherein component B is a compound selected from a) a pyrethroid selected from the group consisting of permethrin, cypermethrin, fenvalerate, esfenvalerate, deltamethrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, bifenthrin, fenpropathrin, cyfluthrin, tefluthrin, ethofenprox, natural pyrethrin, tetramethrin, S-bioallethrin, fenfluthrin, prallethrin and 5-benzyl-3-furylmethyl-(E)-(1R,3S)-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropane carboxylate;b) an organophosphate selected from the group consisting of sulprofos, acephate, methyl parathion, azinphos-methyl, demeton-s-methyl, heptenophos, thiometon, fenamiphos, monocrotophos, profenofos, triazophos, methamidophos, dimethoate, phosphamidon, malathion, chlorpyrifos, phosalone, terbufos, fensulfothion, fonofos, phorate, phoxim, pirimiphos-methyl, pirimiphos-ethyl, fenitrothion, fosthiazate and diazinon;c) a carbamate selected from the group consisting of pirimicarb, triazamate, cloethocarb, carbofuran, furathiocarb, ethiofencarb, aldicarb, thiofurox, carbosulfan, bendiocarb, fenobucarb, propoxur, methomyl and oxamyl;d) a benzoyl urea selected from the group consisting of diflubenzuron, triflumuron, hexaflumuron, flufenoxuron, lufenuron and chlorfluazuron;e) an organic tin compound selected from the group consisting of cyhexatin, fenbutatin oxide and azocyclotin;f) a pyrazole selected from the group consisting of tebufenpyrad and fenpyroximate;g) a macrolide selected from the group consisting of abamectin, emamectin, ivermectin, milbemycin, spinosad, azadirachtin and spinetoram;h) an organochlorine compound selected from the group consisting of endosulfan, benzene hexachloride, DDT, chlordane and dieldrin;i) an amidine selected from the group consisting of chlordimeform and amitraz;j) a fumigant agent selected from the group consisting of chloropicrin, dichloropropane, methyl bromide and metam;k) a neonicotinoid compound selected from the group consisting of imidacloprid, thiacloprid, acetamiprid, nitenpyram, dinotefuran, thiamethoxam, clothianidin, nithiazine and flonicamid;l) a diacylhydrazine, selected from the group consisting of tebufenozide, chromafenozide and methoxyfenozide;m) a diphenyl ether selected from the group consisting of diofenolan and pyriproxyfen;n) Indoxacarb;o) chlorfenapyr;p) pymetrozine;q) spirotetramat, spirodiclofen and spiromesifen;r) a diamide selected from the group consisting of flubendiamide, chlorantraniliprole and cyantraniliprole;s) sulfoxaflor;t) metaflumizone;u) fipronil and ethiprole;v) pyrifluqinazon;w) buprofezin;x) diafenthiuron;y) 4-[(6-Chloro-pyridin-3-ylmethyl)-(2,2-difluoro-ethyl)-amino]-5H-furan-2-one; andz) Bacillus firmus, Bacillus cereus, Bacillus subtilis, and Pasteuria penetrans.
  • 9. A pesticidal mixture according to claim 1, wherein component B is a compound selected from pymetrozine;an organophosphate selected from the group consisting of sulprofos, acephate, methyl parathion, azinphos-methyl, demeton-s-methyl, heptenophos, thiometon, fenamiphos, monocrotophos, profenofos, triazophos, methamidophos, dimethoate, phosphamidon, malathion, chlorpyrifos, phosalone, terbufos, fensulfothion, fonofos, phorate, phoxim, pirimiphos-methyl, pirimiphos-ethyl, fenitrothion, fosthiazate and diazinon;a pyrethroid selected from the group consisting of permethrin, cypermethrin, fenvalerate, esfenvalerate, deltamethrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, bifenthrin, fenpropathrin, cyfluthrin, tefluthrin, ethofenprox, natural pyrethrin, tetramethrin, S-bioallethrin, fenfluthrin, prallethrin and 5-benzyl-3-furylmethyl-(E)-(1R,3S)-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropane carboxylate;a macrolide selected from the group consisting of abamectin, emamectin, ivermectin, milbemycin, spinosad, azadirachtin and spinetoram;a diamide selected from the group consisting of flubendiamide, chlorantraniliprole and cyantraniliprole;a neonicotinoid compound selected from the group consisting of imidacloprid, thiacloprid, acetamiprid, nitenpyram, dinotefuran, thiamethoxam, clothianidin, nithiazine and flonicamid;spirotetramat, spirodiclofen and spiromesifen; andsulfoxaflor, lufeneron, diafenthiuron, and fipronil.
  • 10. A pesticidal mixture according to claim 1, wherein component B is a compound selected from the group consisting of abamectin, chlorpyrifos, cyantraniliprole, emamectin, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid, chlorantraniliprole, flonicamid. Sulfoxaflor, Lufeneron, Diafenthiuron, Flubendiamide, Tefluthrin, and Fipronil
  • 11. A pesticidal mixture according to claim 1, wherein component B is a compound selected from the group consisting of abamectin, chlorpyrifos, cyantraniliprole, emamectin, lambda cyhalothrin, pymetrozine, spirotetramat, thiamethoxam, clothianidin, imidacloprid and flonicamid.
  • 12. A pesticidal mixture according to claim 1, wherein the mixture comprises an agricultural acceptable carrier and optionally a surfactant.
  • 13. A pesticidal mixture according to claim 1, wherein the weight ratio of A to B is 1000:1 to 1:1000.
  • 14. A method of controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest a combination of components A and B, wherein components A and B are as defined in claim 1.
  • 15. A seed comprising a mixture as defined in claim 1.
  • 16. A method comprising coating a seed with a mixture as defined in claim 1.
Priority Claims (4)
Number Date Country Kind
10250337.2 Feb 2010 EP regional
1007689.1 May 2010 GB national
10164231.2 May 2010 EP regional
10187269.5 Oct 2010 EP regional
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2011/051511 2/3/2011 WO 00 11/13/2012